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GENERAL INTRODUCTION
   Sedative hypnotics, barbiturates and benzodiazepines, are widespread in clinical
therapy. Barbiturates have been derived from barbituric acid, a chemical discovered
in 1863 by von Baeyer (Henningfield and Ator, 1986a), Forty years later, two German
scientists, Fischer and von Mering, used von Baeyer's acid to synthesize a new drug
which they called barbital. Before synthesis of barbital, many researcher$ had been
Iooking for a drug that would combat the effects of anxiety and nervousness (Rall,
1990). Although some drugs succeeded to combat the effects of anxiety and
nervousness, these drugs induced the side effects such as narcosis (like morphine
and codeine), chronic toxicity (Iike bromide salts) and user bad breath (like chloral
hydrate) (Henningfield and Ator, 1986a). Since barbiturates are tasteless, odorless
and do not give the user bad breath, and show the anxiolytic and hypnotic effects at
low and hjgh doses, respectively, barbiturates had been widely used as a useful, safe
and low-side effect sedative hypnotics from the beginning to middle of 20th century,
and several popular old drugs (bromide salts, chioride hydrate, paraldehyde,
urethane and sulfonal) have slipped into oblMon (Henningfield and Ator, 1986a; Rall,
1990; Yutrzenka and Patrick, 1992). Moreover, the partial separation of sedative-
hypnotic-anesthetic from anticonvulsant properties, was embodied in phenobarbital
(Rall, 1990). Unfortunately, the profound complications, such as deaths by
overdosages, abuse and physical dependence, associated with barbiturates use
became apparent at middle of 20th century (Henningfield and Ator, 1986a; Miller,
1991; Yutrzenka and Patrick, 1992). For instance, during the mid-1950's, 70 O/o of all
admissions at the poison treatment center in Copenhagen, Denmark, were due to
barbiturates overdosages (Henningfield and Ator, 1986a). Moreover, from the 1950's,
the illicit use (nonmedical use) of barbiturates was epidemic and was becoming an
accepted way to get "high" ÅqHenningfield and Ator, 1986c). Additionally, anxiolytics,
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anticonvulsants and hypnotics such as barbiturates, meprobamate and
trimethadione, which have been used at that time, have been reported to possess the
tolerance and physical dependence liability (Rall, 1990). On 1960, chlordiazepoxide
was developed by Roche as the first compound of benzodiazepines and then many
of benzodiazepines have been synthesized (Miller and Greenblatt, 1992; Rall, 1990).
Because toxicity and dependence liability of benzodiazepines are weaker than those
of barbiturates, benzodiazepines are now widely used as anxiolytics, anticonvulsants,
hypnotics and muscle-relaxants, selecting for individual pharmacological profiles,
and have largely replaced barbiturates and other sedative hypnotics (Mjller and
Greenblatt, 1992; Rall, 1990). Today, barbiturates are scarcely used, except for
phenobarbital as an antiepileptic in clinical therapy and pentobarbital as an
anesthetic in animal studies (Rall, 1990).
   Sedative hypnotics, barbiturates and benzodiazepines, commonly show the
anxiolytic, anticonvulsant, muscle-relaxant and hypnotic effects, memory impairment
and hypothermia in human and experimental animals (Rall, 1990). Action sites of
these drugs have been accepted to be the respective binding sites on GABAA '
benzodiazepine receptor / Cl- channel complex. GABAA ' benzodiazepine receptor 1
Cl- channel cornplex consists of five subunits of GABAA receptor, containing Cl-
channel as a core (Doble and Martin, 1992), The subunits of GABAA receptor are
grouped into five sequence classes (ct, S, y, 6 and p) with most classes containing
SeVeral variants: alm6, Bl-4, yl-3 (Doble and Martin, 1992; Wafford et al., 1992). It is
known that two a subunits and two S subunits must be present in the native GABAA '
benzodiazepine receptor / Cl' channel complex (Doble and Martin, 1992). The
recognition sites for GABAA agonists is present on the P subunit of the GABAA
receptor, and one ct subunit and one 6 subunit of GABAA receptor may be required to
the positive responses of GABAA agonists (Casalotti et al., 1986), On the other hand,
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the recognition sites for benzodiazepine agonists are present on the ct subunit of the
GABAA receptor, and one ct subunit, one S subunit and one y subunit may be
required to the positive responses of benzodiazepine agonists (Ymer et al., 1990År.
Therefore, there are many types of GABAA ' benzodiazepjne receptor l Cl- channel
complex consisted with various combination of the subunits of GABAA receptor.
GABAA agonists, barbiturates and benzodiazepine agonists may be considered to
bind respective GABAA ' benzodiazepine receptor / Cl- channel complex according to
the own selectivity to the subunit of GABAA receptor. For example, in the studies
(Luddens and Wisden, 1991) using the recombinant GABAA ' benzodiazepine
receptor / Clm channel complex consisting ct,B2y2 subunits of GABAA receptor,
benzodiazepine agonists, benzodiazepine antagonists and benzodiazepine inverse
agonists show the individual selectivities to a subunits of GABAA receptor as follows:
diazepam and flunitrazepam (cti = ct2 = ct3 = ors), zolpidem and alpidem (cti År ct2 = ct3
ÅrÅr as), flumazenil (ai = a2 = a3 = cts År ct6), Ro 15-4513 (cti = a2 = a3 = cts = ct6), S-
carboline analogues FG 7142, P-CCE and DMCM (cti År ct2 = ct3 År as År ct6)• HOWeVer,
the efficacy of these drugs may be related not only to the selectMty to the ct subunits
of GABAA receptor but also to the combination of a,Syy, subunits of GABAA receptor
(Ducic et al., 1993). Recently, the relation of pharmacological profiIe of these drugs in
behavioral study to the combination of ct,6yy, subunits of GABAA receptor has been
beginning to be determined. In these researches, it was suggested that anxolytic and
anticonvulsant effects of these drugs may be mediated by cti6yy2 subunits of GABAA
receptor, sedative and muscle-ralaxant effects of these drugs may be mediated by
a2,3,seyy2 sUbunits of GABAA receptor, and hypnotic effect of these drugs may be
mediated by ct6Byy2 subunits of GABAA receptor (Doble and Martin, 1992; Guidotti et
al., 1990; Luddens et al., 1990). Since the selectivity of these drugs to respective ct
subunits of GABAA receptor disappeared at high doses of these drugs, and the
densities of respective GABAA ' benzodiazepine receptor 1 Cl- channel complex in
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various brain regions are not necessarily to be related to the behavioral
pharmacological profiIe of respective brain regions (Doble and Martin, 1992; Potier et
al., 1988), it is still difficult to explain the mechanisms for producing the behavioral
characterization of these drugs, today.
   Barbiturates and benzodiazepines bind to respective binding sites on GABAA '
benzodiazepine receptor / Clm channel complex in the nerve terminals or cell bodies
of other neurotransmitter-related neurons, and increase Cl' influx in the nerve
terminals and cell bodies (Akaike, 1989; Harrison et al., 1988). In the nerve terminals
of other neurotransmitter-related neurons, the equilibrium potential of Cl' on cell
membrane is high (--30 - -40 mV), since intracellular Cl- concentration is high
(Akaike, 1989). Therefore, the Cl- which gets into a cell through Cl" channels,
induces the depolarization of cell membrane and blocks the Na' channels; as a
result, Ca2' influx through the voltage-dependent Ca2' channels on the nerve
terminals is indirectly suppre$sed (Akaike, 1989; Maruyama et ai., 1988). In the nerve
terminals, the Ca2' which gets into a cell through voltage-dependent Ca2' channels,
mediates release of neurotransmitters from nerve terminals (Rogawski and Porter,
1990). By the above mechanisms, which called presynaptjc inhibitjon, barbiturates
and benzodiazepines suppress the release of neurotransmitters (Akaike, 1989;
Maruyama et al., 1988). On the other hand, in the cell bodies of other
neurotransmitter-related neurons, increase in Cl- influx induces the inhibitory
postsynaptic potential and produces the hyperpolarization of cell membrane; as a
result, Ca2' influx through the voltage-dependent Ca2' channels on the ceil bodies is
djrectly suppressed ÅqHarrison et al., 1988). Therefore barbiturates and
benzodiazepines suppress the postsynaptic neuron activities by inhibiting the
depolarization of cell membranes of postsynaptic neurons, that is called postsynaptic
inhibition (Harrison et al., 1988). As shown by the above findings, presynaptic and
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postsynaptic inhibitions by barbiturates and benzodiazepines are due to inhibition of
Ca2' infiux through the voltage-dependent Ca2' channels. On the other hand, it is
considered that the Ca2' which gets into a cell through voltage-dependent Ca2'
channels, binds to calmodulin and activates phosphatase. Activated phosphatase
induces the dephosphorylation of ATP-sensitive phosphorylation sites in S subunit of
GABAA receptor; as a result, the increased intracellular Ca2' may suppress GABA
response which is induced by barbiturates and benzodiazepines (Akaike et al., 1989;
Yakushiji et al., 1987). Therefore, intracellular Ca2' may play a very important role on
the appearance of central depressing effects of barbiturates and benzodiazepines.
Barbiturates and benzodiazepines suppress the release of neurotransmitters from
nerve terminals, and suppress the cell body firing rates of several neurons (Rogawski
and Porter, 1990). It is believed that central depressing effects of barbiturates and
benzodiazepines are due to this suppression of several neuron activities in the brain.
Anxiolytic effects of these drugs may be derived from due to the suppression of the
actMties of ascending serotonergic neurons from raphe neucleus to amygdala
(Blackburn, 1992; Costall and Naylor, 1991; Costall et al., 1989b). Moreover, memory
impairment of these drugs may be derived from suppression of cholinergic neuron
actMties in hippocampus (Nabeshima et al., 1990; Tohyama et al., 1991). However,
anticonvulsant, muscle-relaxant and sedative effects of these drugs can not yet be
completely characterized by specific neurotransmitters and brain regions, Sedative
hypnotics, especially benzodiazepines, are widely used in clinical therapy. Therefore,
there is a possibility that these sedative hypnotics may be used concurrently with
other drugs which affect central nervous system. In fact, barbiturates and
benzodiazepines are used concurrently with other anticonvulsants (e.g. phenytoin
and carbamazepine) in epilepsy therapy ÅqDelgado-Escueta and Enrile-Bacsal,
1983). Moreover, benzodiazepines are used concurrently with antidepressants
(tricyclic and tetracyclic antidepressants) (Nutt and Glue, 1991) or antipsychotic
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drugs (e.g. haloperidol) (Tamminga and Gerlach, 1987) in anxiety and depression or
schizophrenia therapy, respectively. These drugs combined with barbiturates or
benzodiazepines have their own effects mediated by neurotransmitters directly or
indirectly (through ion channels). Therefore, it is possible that the combined drugs
affect the efficacy and dependence liability of these sedative hypnotics. However,
there are few reports that these drug interactions and their mechanisms have been
determined.
   Sedative hypnotics, barbiturates and benzodiazepines are known to possess the
same physical dependence liab"ity. Physical dependence of these drugs are
categorized in the same class of substance dependence, barbiturates type, by the
World Health Organization (Kramer and Cameron, 1975). As a generalization, the
withdrawal signs seen after cessation of a drug tends to be opposite to the signs
produced by acute administration of that drug (Nutt et al., 1991). Therefore,
withdrawal signs of sedative hypnotics are characterized by apprehension, high-
excitability, loss of appetite, piloerection (hair standing on end), muscle rigidity,
impaired motor actMty, retching, vomiting, weight loss, tremor, convulsion, delirium,
hallucinations and hyperthermia (Henningfield and Ator, 1986b). The development of
physical dependence on these drugs is related to the frequency, duration and dosage
of the treatment (Suzuki, 1990; Woods et al., 1992), The withdrawal signs of sedative
hypnotics with more frequency or greater intensity appear following administration of
higher doses or doses with greater effects, longer duration of treatment, or
continuous rather than intermittent drug administration (Woods et al., 1992).
Barbiturates and benzodiazepines are classified to 3 groups for their half life as
follows; short-acting Åqbarbiturates: 4 hr or less, benzodiazepines: 6 hr or less),
intermediate-acting (barbiturates: 4-6 hr, benzodiazepines: 6-20 hr) and long-
acting (barbiturates: 6 or more hr, benzodiazepines: 20 or more hr) (Henningfield and
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Ator, 1986a; Rall, 1990). Long-acting barbiturates and benzodiazepines are easy to
develop the physical dependence rather than short-acting barbiturates and
benzodiazepines, because the brain concentration of long-acting drugs is maintained
for a longer time by single injection, but short-acting drugs are required several
injections to maintain the brain concentration for the same time (Henningfield and
Ator, 1986a; Hollister, 1985). On the other hand, the intensities of physical
dependence on short-acting barbiturates and benzodiazepines are stronger than
those on long-acting barbiturates and benzodiazepines, because severities of
withdrawal signs of barbiturates and benzodiazepines correlate to the disappearance
rate of these drugs from the brain after withdrawal (Henningfield and Ator, 1986a;
Hollister, 1985).
   Physical dependence on these drugs have been evaluated so far in various
animal species and by various experimental methods (Suzuki, 1990; Woods et al.,
1992). These studies have been started with dogs in 1931. Seevers and Tatum
(1931) reported that several withdrawal signs (including convulsions) were observed
in dogs after the chronic intragastric injection of barbital. Moreover, Fraser and lsbell
(1954) achieved to develop the physical dependence on several barbiturates
(secobarbital, pentobarbital and barbital) in dogs. In those days, the evaluation of
physical dependence on barbiturates were also examined using the monkeys,
baboons and cats, but not rodents; therefore, a Iot of money was required for the
evaluation, ln 1960's, the evaluations using the rodents, rats and mice, were feasible.
Crossland and Leonard (1963) and Essig (1966) succeeded to develop barbital
physical dependence and to induce the withdrawal convulsion in rats using a drinking
method. Kaneto et al. (1973) reported that barbital withdrawal signs 'were observed in
mice after oral treatment with barbital for 1O days. It was also reported by Yoshimura
and Yamamoto (1979) that phenobarbital withdrawal signs appeared after oral
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treatment with phenobarbital for 10 weeks. However, these procedures require
prolonged treatment with barbiturates to develop the physical dependence (Fraser
and lsbell, 1954; Seevers and Tatum, 1931; Yoshimura and Yamamoto, 1979), and
the intensity of withdrawal signs observed in these procedures is so weak (Kaneto et
al., 1973; Yoshimura and Yamamoto, 1979). Importantly, these procedures can not
develop physical dependence on benzodiazepines, ln 1970's, Tagashira et al. (1978)
reported that natural withdrawal signs (including tremor and convulsions) of
barbiturates were observed in rats chronically treated with barbiturates using a drug-
admixed food method. Using this method, Suzuki et al. (1992a) established animal
models of physical dependence on benzodiazepines in rats. This method has
successfully induced severe natural withdrawal signs, including tremors and
convulsions in rats, but this procedure requires a prolonged and continuous exposure
to barbiturates and benzodiazepines (at least 1 month) (Suzuki et al., 1992a; 1992b;
Woods et al., 1992). In the cases of opioids such as morphine, evaluations of
physical dependence on opioids in rodents are generally determined using the
precipitation of opioid withdrawal by opioid antagonists such as naloxone (Suzuki,
1990). However, the studies with antagonists of barbiturates and benzodiazepines
have hardly progressed as compared with opioids, partly because competitive
antagonists of barbiturates and benzodiazepines have not been available. Recently,
competitive antagonists of benzodiazepines, flumazenii (benzodiazepine analogue)
and ZK 93426 (B-carboline analogue), were synthesized and began to use to
evaluate physical dependence on benzodiazepines (Little et al., 1987). Lukas and
Griffiths (1982) reported that treatment with flumazenil was able to precipitate the
withdrawal signs of diazepam in baboons after intragastric injection of diazepam for 7
days. Moreover, Loscher et al. (1989) reported that treatment with ZK 93426 was
also able to precipitate the withdrawal signs of diazepam in dogs after treatment with
diazepam for 7 days. Although the two antagonists precipitate withdrawal signs, the
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signs of withdrawal observed are somewhat different (Loscher et al., 1989).
Withdrawal by flumazenil produced rigidity in posture and walking with increased
muscle tone, tremor, twitches and jerks. In contrast, ZK 93426 induced myocionic
jerks and clonic-tonic seizures but did not alter motility. The investigators noted that
the withdrawal signs observed after ZK 93426 were similar to those observed after
natural withdrawal, whereas the rigid postures and immobility observed after
flumazenil were unique signs which may be due to its partial agonistic efficacy
(Woods et al., 1992), Unfortunately, the precipitation of benzodiazepine withdrawal
signs using ZK 93426 has been reported only in dogs, but not in rodents (Loscher et
al., 1989). Moreover, to get appearance of severe precipitated withdrawal signs
(including convulsions) of benzodiazepines by flumazenil, prolonged exposure to
benzodiazepines (for about 1 month) is required in rodents (Little et al., 1992; Woods
et al., 1992). Recently, it has been shown that chronic treatment with
benzodiazepines in mice causes supersensitivity to proconvulsant effect of
benzodiazepine partial inverse agonist FG 7142 following termination of the
treatment with benzodiazepines (Lister and Nutt, 1986; Little, 1988; Little et al., 1988;
Nutt and Costello, 1988). The supersensitivity to FG 7142 lasts for 24 hr to 1 week
after the last treatment with benzodiazepines ÅqLittle et al., 1988); this period coincides
with the period that natural withdrawal signs of benzodiazepines appear (Suzuki et
al., 1992a). Since this procedure requires only 1 week, the production of convulsions
by FG 7142 at proconvulsant doses after chronic treatment with benzodiazepines in
rodents has been accepted as a reliable and useful, although preliminary, index for
evaluating benzodiazepine-like physical dependence liability (Lister and Nutt, 1986;
Little, 1988; Little et al., 1988; Moreau et al., 1990; Nutt and Costello, 1988; Piot et
al,, 1990).
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   The object of the proposed research is the investigation on the involvement of
some neuromodulations, especially changes in the actMties of noradrenergic and
serotonergic neurons and adaptations of some 5-HT receptors and Ca2' channels, in
the development of physical dependence on barbiturates and benzodiazepines,
which commonly affect GABAA ' benzodiazepine receptor1 Cl- channel complex, and
the dependence of which are categorized in the same class of substance
dependence "barbiturates type". The detailed aims of the proposed research are:
(t) To determine how monoamine-related neuromodulations are involved in the
   physical dependence on barbiturates, the effects of different types of
   antidepressants (monoamine re-uptake inhibitors) on the development of
   physical dependence on barbital were investigated.
(2) To determine the involvement of adaptation of 5-HT receptors in the physical
   dependence on benzodiazepines, the effects of the several serotonergic
   anxiolytics which act through different subtypes of 5-HT receptors on the
   development of physical dependence on diazepam were investigated.
(3) To determine the involvement of brain Ca2' channels in the physical dependence
   on barbkurates and benzodiazepines, the effects of several Ca2' channel
   blockers which block different types of Ca2' channels both on the development of
   physical dependence on barbital and diazepam, and on the appearance of
   barbital withdrawal signs were investigated.
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CHAPTER 1
EFFECTS OFANTIDEPRESSANTS ON THE CENTRAL DEPRESSION BYAND
THE DEVELOPMENT OF PHYSICAL DEPENDENCE ON BARBITAL IN RATS
In troduction
   Barbiturates are widely known to possess physical dependence Iiability. Physical
dependence on barbiturates has been evaluated in various animal species and with
various experimental methods (Suzuki, 1990). Biochemical changes associated with
barbiturate dependence and after withdrawal from barbiturates have been
determined, and the effects of psychotropic drugs on physical dependence on
barbiturates have been examined. Several reports have indicated that changes in
brain monoamine concentrations and monoamlne-related neuron actMties may be
involved in physical dependence on barbiturates.
   Morgan et al. (1977, 1978) suggested that brain DA concentrations increase after
barbital withdrawal, and that ct-methyl-p-tyrosine suppresses barbital withdrawal
convulsjons. Tagashira et al. (1983a) reported that barbital withdrawal convulsions
are suppressed by disulfiram, which decreases brain NE concentrations, Moreover,
they found that 5-HT turnover increases after barbital withdrawal, and that this
increase in 5-HT turnover and barbital withdrawal convulsions are suppressed by
nitrazepam (Tagashira et al., 1982a). Therefore, it is believed that the concentrations
and/or turnovers of 5-HT, NE and DA increase after barbiturate withdrawal, and that
the increases in brain monoamine concentrations and monoamine-related neuron
activities may be directly involved in the appearance of barbiturate withdrawal signs.
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   On the other hand, co-administration of ct-methyl-p-tyrosine or reserpine during
barbital treatment potentiates the development of physical dependence on barbital
(Tagashira et al., 1983b). WhUe, co-administration of methamphetamine or p-
chlorophenylalanine suppresses the development of physical dependence on barbital
(Tagashira et al., 1983b). Therefore, the changes in brain monoamine concentrations
and/or monoamine-related neuron activities may affect not only the appearance of
barbiturate withdrawal signs, but also the development of physical dependence on
barbiturates.
   Tricyclic antidepressants, such as imipramine and desipramine, inhibit the re-
uptake of NE and 5-HT into the terminals of noradrenergic and serotonergic
neurons, and increase 5-HT and NE concentrations in the synaptic lacuna
(Baldessarini, 1990). However, chronic treatment with tricyclic antidepressants
down-regulates 5-HTiA, 5-HT2, a2 and B receptors (Blier and de Montigny, 1980;
Cohen et al., 1982; Fuxe et al., 1983; Heninger and Charney, 1987; Wolfe et al.,
1978). On the other hand, new psychotropic drugs, bifemelane and teniloxazine, are
potent antidepressants (Anami et al., 1985; Tobe et al., 1981), and possess
antianoxic (lzumi and Yasuda, 1985; Tobe et al., 1983), antiischemic (Egawa et al,,
1984) and memory retrieval (Anami et al., 1985; 1987; Tobe et al., 1985) actions.
Moreover, bifemelane inhibits the re-uptake of 5-HT and NE into the nerve terminals
of respective neurons, and affects brain 5-HT and NE concentrations (Egawa et al.,
1983; Ohizumi et al., 1982). While, teniloxazine only inhibits the re-uptake of NE
(Anami et al., 1986).
   Tricyclic antidepressants have been known to potentiate the barbital-induced
central depression, for example, barbital-induced hypnosis (Bahattacharya, 1978;
Baldessarini, 1990; Liu et al., 1975). This potentiation of barbital-induced hypnosis
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by tricyclic antidepressants may be due to the inhibition of monoamine re-uptake
(Bahattacharya, 1978; Liu et al., 1975), ln general, it is considered that increase in
magnitude of barbiturate-induced central depression by combination of a
dependence liability-free drug during the barbiturate treatments, induces the
potentiation of the development of physical dependence on barbiturates (Tagashira
et al., 1981År. Therefore, in the present study, the effects of imipramine, bifemelane
and teniloxazine on barbital-induced hypnosis and on the development of physical
dependence on barbital were examined. Moreover, the effects of imipramine and
bifemelane or teniloxazine on the barbital-induced hypnosis and on the development
of physical dependence on barbital were compared, and the involvement of
monoamine re-uptake inhibition in the development of physical dependence on
barbital was determined.
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EXPERIMENT 1-1: Effects of antidepressants on the central depression by
               barbital in rats
Materials and Methods
Animals
   Male Sprague-Dawley rats (Tokyo Animal Laboratories lnc., Tokyo, Japan) that
weighed 170-290 g at the beginning of the experiment, were used. Animals were
housed individually under a 12 hr light-dark cycle (lights on 8:30 to 20:30) with free
access to food and tap water. The room temperature and the relative humidity were
maintained at 22 Å} 1 OC and 55 Å}5 O/o, respectively.
pmtbtlddH
   Hypnosis induced by barbital (200 mg/kg, i.p.) was measured in rats. Rats were
pretreated with saline (1 ml/kg, i.p.), imipramine (20 mg/kg, i.p.), bifemelane (40
mg/kg, i.p.) or teniloxazine Åq4 mg/kg, i.p.) 30 min before the treatment with barbital.
The onset time of barbital hypnosis was considered to be the time between the
injection of barbitai and loss of the righting reflex, whereas sleep time was defined as
the time between the Ioss and regaining of the righting reflex.
!D2!ygs
   Barbital sodium (Tokyo Chemical lnd., Tokyo, Japan), imipramine hydrochloride
(Sigma Chemical Co., St. Louis, USA), bifemelane hydrochloride (Mitsubishi
ChemicaHnd. Ltd., Yokohama, Japan) or teniloxazine maleate (Yoshitomi
Pharmaceutical lnd. Ltd., Fukuoka, Japan) were dissolved in saline.
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pmttttcalAals
   Analyses for on$et time and sleep time of barbital-induced
performed by Student's t-test.
hypnosis were
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Results
   Table 1-1 shows effects of several antidepressants on barbital-induced
hypnosis, Pretreatment with imipramine or bifemelane significantly prolonged
barbital-induced sleep time (pÅqO.Ol and pÅqO,OOI, respectively). Moreover,
pretreatment with bifemelane also significantly shortened onset time of barbital-
induced hypnosis (pÅqO.Ol). On the other hand, pretreatment with teniloxazine only
significantly prolonged onset time of barbital-induced hypnosis (pÅqO.05), but did not
affect the sleep time of barbital-induced hypnosis.
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Table 1-1
Effects of several antidepressants on barbital-induced hypnosis in rats
Pretreatment Onset time (min) SIeep time (min)
Saline (l ml/kg, i.p.) 4Z5-+ 3.9 209.6Å} 16.3
lmipramine (20 mg/kg, i.p.) 68.3-+ 16.4 420.4-+ 60.4"
Saline(l ml/kg, i.p.) 70.2m+ 7.8 243.6Å}23.8
Bifemelane(40mg/kg, i.p.) 29.1-+ 7.1" 699.1Å}66.9"'
Saline (l ml/kg, i.p.2 4Z5.+ 3.9 209.6Å} 16.3
Teniloxazine (4 mg/kg, i.p.) 89.7Å} 15.6' 195.0Å} 23.0
Rats were pretreated with imipramine, bifemetane or teniloxazine 30 min
prior to barbital iniection (200 mg/kg, i.p.J. Each group consisted of 6
       t ft                     "tanimals. pÅqO.05, pÅqO.Ol, pÅqO.OOI vs. respectivesatine-pretreatedgroup.
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EXPERIMENT 1-2: Effect ora tricyclic antidepressants, imipramine, on the
                development ofphysical dependence on barbital in rats
Materials and Methods
Animals
   Male Sprague-Dawley rats (Tokyo Animal Laboratories lnc,, Tokyo, Japan) that
weighed 21O-290 g at the beginning of the experiment, were used. Animals were
housed individually under the conditions as described in EXPERIMENT 1-1.
QD!ye!gp!!!en!-g!-!2!pta!Pgpens!!uggl tfPh IDd
   To prepare the drug-admixed food, barbital and imipramine were mixed with a
normal powdered food (CA-1, Japan Clea, Tokyo, Japan) in a mortar (Suzuki et al.,
1990, 1992b). Each rat was fed either the barbital alone- or barbital+imipramine-
admixed food for 28 days and could drink tap water ad Iibitum The concentration of
barbital in the food was gradually increased during the treatment (Table 1-2); the
schedule of the barbital treatment was according to the method of Suzuki et al.
(1992bÅr with minor modifications. The concentration of imipramine in the food was
fixed at O.25 mg/g of food. Body weight and food consumption were measured every
day at 16:OO. Daily barbital intake was calculated as follows:
                                   Food intake Drug concentration
                                    Åqg/day) X Åqmglg of food)
        Barbital intake (mg/kglday)
                                         Body weight (kg)
Barbital Withdrawal
   Withdrawal was achieved by substituting normal food for drug-admixed food at
18:OO on the last day of the treatment. Body weight was measured and withdrawal
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signs were observed after termination of the drug treatment, Changes in body weight
after withdrawal were calculated as percent changes from the body weight at the
beginning of withdrawal. To quantify the intensity of physical dependence on barbital,
a rating score for withdrawal signs, according to the method of Suzuki et al. (1992b)
with minor modifications, was used (Table 1-3). Withdrawal scores are the sum of
the rating scores of individual animals, and the withdrawal scores for 204 hr after the
withdrawal are shown as total withdrawal scores.
!D,!!ggs
   Barbital and imipramine hydrochloride were purchased from Wako Pure
Chemical lnd. (Tokyo, Japan) and Sigma Chemical Co. (St. Louis, USA),
respectively.
SS!g!!s!!gaj-tatisticalAnalss
   Analyses for the changes in body weight and withdrawai scores were performed
by two factor (groups x times) repeated measures analysis of variance (ANOVA). All
other analyses were carried out using Student's t-test.
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Table 1-2
Progressively increasing dosage schedute for
development ofphysical dependence on barbital in rats
Barbital concentration
   (mg/g of food)
Duration
 (days7
O.5 and 1.0
1.0 and 2.0
2O and 4.0
4.0 and 6.0
   6.0
4
6
6
6
6
20
Tabte 1-3
Score chart for barbital withdrawat signs
Characteristic signs Score
VVeightloss 5-10e/o
            10-ls o/.
            15%Åq
Pitoerection
Vocalization
lrritability
Aggression
Teeth-chattering
Diarrhea
Muscte rigidity
Straub's tail
Ear-twitch
Lacrimation
Nose-bteed
Fascicular-twitch
Jerk
Tremor
Handiing-elicited convulsion
Spontaneous convulsion
Death
1
2
3
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
4
4
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Results
   There was no significant difference in daily barbital intake during barbital
treatment between the barbital alone and barbital+imipramine groups, The mean
barbital intakes at the final barbital concentration (6 mg/g of food) was 318.6 Å} 7.3
mglkglday for the barbital alone group and 316.3 Å} 6.9 mg/kglday for the barbital+
Imlpramlne group.
   After termination of the barbital treatment, several withdrawal signs were
observed. These signs included body weight Ioss, piloerection, vocalization,
irritability, aggression, muscle rigidity, Straub's tail, ear-twitching, teeth-chattering,
fascicular-twitch, Iacrimation, nose-bleed, jerk, tremor, handling-elicited
convulsions, spontaneous convulsions and death. Total withdrawal scores after
barbital withdrawal in the barbital alone and barbital+imipramine groups were 26.8 Å}
1.9 and 31.8 Å} 2.1, respectively (Fig. 1-1). The total withdrawal scores were
significantly potentiated by co-administration of imipramine (pÅqO.05). Figure 1-2
shows the time course changes in withdrawal scores after termination of the barbital
treatment. Withdrawal scores were also significantly potentiated by co-
administration of imipramine (F[1,133]=23.604, pÅqO.Ol). As shown in Fig. 1-3, body
weight decreased after termination of the barbital treatment. The maximum weight
loss was 7.20 Å} 1.04 O/o at 72 hr afterwithdrawal in the barbital alone group and 1O.40
Å} 1.81 O/o at 72 hr after withdrawal in the barbital+imipramine group. Weight loss after
the withdrawal was significantly increased by co-administration of imipramine
ÅqF[1 ,1 33]=47.861, pÅqO.Ol),
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Time course changes in withdrawai scores after withdrawal from treatment
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Time course changes in body weight toss (O/o) after withdrawal from treatment
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EXPERIMENT 1-3: Effects of newantidepressants, bifemelane and
                teniloxazine, on the development ofphysical dependence
                on barbital in rats
Materiais and Methods
Animals
   Male Sprague-Dawley rats (Tokyo Animal Laboratories lnc., Tokyo, Japan) that
weighed 170-200 g at the beginning of the experiment, were used. Animals were
housed individually under the conditions as described in EXPERIMENT 1-1 .
!DS!cptgp!peg!g!-!2!!ysjgg!Per2gnptgngee1 tofPh IDd
   As described in EXPERIMENT 1-2, barbital aione-, barbital+bifemelane- or
barbital+teniloxazine-admixed food was prepared. Each rat was fed any of drugs-
admixed foods for 28 days and could drink tap water ad libitum. The concentration of
barbital in the food was gradually increased during the treatment according to
EXPERIMENT 1-2. The concentrations of bifemelane and teniloxazine in the food
were fixed at 1,O and O.5 mg!g of food, respectively. Body weight and food
consumption were measured everyday at 16:OO. Daily barbital intake was calculated
according to EXPERIMENT 1-2.
Barbital Withdrawal
   Withdrawal was conducted according to EXPERIMENT 1-2. Body weight was
measured and withdrawal signs were observed after termination of the drug
treatment. Changes in body weight and withdrawal scores after withdrawal were
calculated according to EXPERIMENT 1-2. The withdrawal scores for 156 hr after
the withdrawal are shown as total withdrawal scores.
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!D,!!!,!gss
   Barbital was purchased from Wako Pure Chemical lnd. (Tokyo, Japan), and
bifemelane hydrochloride and teniloxazine maleate were supplied from Mitsubishi
Chemical lnd. Ltd. (Yokohama, Japan) and Yoshitomi Pharmaceutical lnd, Ltd.
(Fukuoka, Japan), respectively.
pmtttstclA1i
   Analysis of the incidence of withdrawal signs was performed using the chi-
square (2 x 2) test. Analyses for the changes in body weight and withdrawal scores
were performed by two factor (groups x times) repeated measures analysis of
variance (ANOVA). All other analy$es were carried out using Student's t-test.
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Resuits
   There was no significant difference in daily barbital intake during barbital
treatment between the barbital alone- and barbital+bifemelane or barbital+
teniloxazine group. The mean barbital intakes at the final barbital concentration (6
mglg of food) in the barbital alone, barbital+bifemelane and barbital+teniloxazine
groups were 298.9 Å} 13.6, 344.5 Å} 10.5 and 330.2 Å} 14.4 mg/kglday, respectively.
   After termination of the barbital treatment, several withdrawal signs were
observed (Table 1-4). The incidence of all withdrawal signs were not affected by co-
administration of bifemelane or teniloxazine, Figure 1-4 shows the time course
changes in withdrawal scores after termination of the barbital treatment. The
maximum withdrawal scores in the barbital alone, barbital+bifemelane and barbital+
teniloxazine groups were 20,2 Å} 3.0 (at 42 hr after withdrawal), 20.0 Å} 3,7 (at 39 hr
after withdrawal) and 19.2 Å} 2.5 (at 36 hr after withdrawal), respectively. Co-
administration of bifemelane or teniloxazine did not affect the withdrawal scores. The
total withdrawal scores after barbital withdrawal in the barbital alone, barbital+
bifemelane and barbital+teniloxazine groups were 30.2 Å} 1 .7, 30.2 Å}2.2 and 27.8 Å}2.2,
respectively (Table 1-4). There was no significant difference in the total withdrawal
scores between barbital alone and barbital+bifemelane or barbital+teniloxazine
groups, Body weight of animals in all groups slightly increased immediately after the
withdrawal, and then decreased abruptly, The maximum weight losses in the barbital
alone, barbital+bifemelane and barbital+teniloxazine groups were 7.95 Å} 1 .49 O/o (at 54
hr after withdrawal), 8.47 Å} 1.54 O/o (at 45 hr after withdrawal) and 8.20 Å} 1,28 O/o (at 45
hr after withdrawal), respectively; then body weight gradually increased and regained
to the levels of the beginning of withdrawal at 108 hr after withdrawal. Co-
administration of bifemelane or teniloxazine did not affect the weight loss after
28
withdrawal.
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Tabre 1-4
Behavioral withdrawal signs for 156 hr after the termination of treatment with
barbital alone, barbital+bifemelane or barbitat+tenitoxazine in rats
Positive animals / Total number of animats
VVith dra wal signs
    (scores) Barbital Barbital+
Bifemelane
Barbita/+
Teniloxazine
Weight loss
      s-lo o/o (IJ
      10-15 e/. (2)
      15 O/o Åq (3J
Pitoerection (2)
Vocalization (2J
irritability (2)
Aggression (2)
Diarrhea (2)
Teeth-chattering (2J
Muscle rigidity (2)
Straub's tait (2J
Ear-twitch (2)
Lacrimation (3)
Nose-bleed (3)
Fascicular-twitch (3)
Jerk (3)
Tremor (3)
Convulsion
  Handling-elicited (3)
  Spontaneous (4)
Death (4)
2/6
3/6
O/6
6/6
6/6
6/6
2/6
O/6
4/6
6/6
6/6
6/6
O/6
6/6
6/6
6/6
5/6
5/6
O/6
O/6
3/6
3/6
O/6
6/6
6/6
5/6
1/6
O/6
4/6
6/6
6/6
6/6
O/6
6/6
6/6
6/6
5/6
5/6
1/6
O/6
216
3/6
O/6
6/6
5/6
5/6
3/6
O/6
4/6
6/6
6/6
6/6
1/6
5/6
6/6
6/6
4/6
a6
1/6
O/6
Total vvithdravval scores 30.2
-+ 1.7
30.2
-+ 22
27.8
-+ 22
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Fig. 1-4
Time course changes in withdrawal scores after withdrawal from treatment
vvith barbital (BarJ alone, barbital+bifemelane (Bif; 1.0 mg/g of food) or
barbital+teniloxazine (Ten; O.5 mg/g of food). Each point represents the
mean of 6 observations.
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Discussion
   The mechanism of barbiturate-induced hypnosis has not yet been clarified.
However, several reports have suggested that barbiturate-induced hypnosis is
affected by changes in the brain 5-HT concentrations. Barbiturates are known to
inhibit the metabolism of 5-HIAAId (a metabolite of 5-HT) to 5-HTOL, as a result,
the concentrations of 5-HT increase (Fukumori et al., 1979: Tabakoff and Erwin,
1970). Pretreatment with 5-HT potentiates barbiturate-induced hypnosis, while
pretreatment with p-chlorophenylalanine, a 5-HT-synthesis inhibitor, suppresses it
(Jouvet, 1969). Moreover, tricyclic antidepressants, imipramine and desipramine,
which possess 5-HT and NE re-uptake inhibiting actions, potentiate the barbiturate-
induced hypnosis (Baldessarini, 1990; Bhattacharya, 1978; Liu et al., 1975), and this
potentiation of barbiturate-induced hypnosis by the tricyclic antidepressants was
suppressed by co-treatment with methysergide, a 5-HT antagonist and p-
chlorophenylalanine (Bhattacharya, 1978). Based on these findings, it has been
considered that barbiturate-induced hypnosis is potentiated by an increase in the 5-
HT concentrations, but is suppressed by a decrease in the 5-HT concentrations. In
the present study, pretreatment with imipramine and bifemelane, but not teniloxazine,
potentiated barbital-induced hypnosis. Imipramine and bifemelane lnhibit the re-
uptakes of 5-HT and NE into the nerve terminals of noradrenergic and serotonergic
neurons, which increases 5-HT and NE concentrations in the synaptic lacuna of
cortex and hippocampus (Baldessarini, 1990; Egawa et al., 1983), While
teniloxazine only inhibits the re-uptake of NE (Anami et al., 1986). Therefore, the
potentiating effects of imipramine and bifemelane on barbital-induced hypnosis may
be due to an increase in 5-HT concentrations induced by its 5-HT re-uptake
inhibition. In the present study, teniloxazine slightly prolonged onset time of barbital-
induced hypnosis. Since teniloxazine possesses 5-HT receptor antagonistic action
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(Anami et al., 1987), this effect of teniloxazine observed may have resulted from 5-
HT receptor blockade.
   ln general, the severity of physical dependence on barbiturates is related to the
magnitude of central depression during the treatment. For example, Tagashira et al.
(1981) reported that increase in the magnitude of central depression by combination
of a dependence liability-free drug such as chlorpromazine during the phenobarbital
treatment, induces the potentiation of the development of physical dependence on
phenobarbital. However, in the present study, pretreatment with both imipramine and
bifemelane potentiated the central depressing effect of barbital, but the development
of physical dependence on barbital was potentiated only by co-administration of
imipramine. The potentiating effects of both imipramine and bifemelane on the
barbital-induced central depression may be due to thejr re-uptake inhibition of 5-HT.
Therefore, increase of magnitude of central depression by chronic drug combination
during barbital treatment, may not relate to the development of physical dependence
on barbital. The differences in the effects of imipramine and bifemelane on the
development of physical dependence on barbital may be due to the differences of
both drugs in other pharmacological profiies.
   Physical dependence on barbiturates may involve changes in brain monoamine
concentrations and in the activities of monoamine-related neurons. Barbiturates
suppress NE and DA release from nerve terminals (Rogawski and Porter, 1990),
and chronic treatment with barbiturates decreases DA and NE concentrations in the
brain (Morgan et al., 1977; 1978; Tagashira et al., 1983a). After withdrawal from
barbiturates, the release of NE and DA from nerve terminals increases, and
barbiturate withdrawal signs are suppressed by decreases in NE and DA
concentrations (Morgan et al., 1977; 1978; Tagashira et al., 1983a). Moreover, the
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development of physical dependence on barbiturates is potentiated by further
reduction of brain NE and DA concentrations induced by co-administration of ct-
methyl-p-tyrosine or reserpine (Tagashira et al., i983b), but js suppressed by a
recovery from the decrease in brain NE and DA concentrations induced by co-
administration of methamphetamine (Tagashira et al., 1983b). Therefore, the
development of physical dependence on barbital is potentiated and suppressed by
further inhibition and enhancement of noradrenergic neuron actMty, respectively.
   Barbiturates suppress 5-HT release (Rogawski and Porter, 1990), but increase
5-HT and 5-HIAAId concentrations in synaptic Iacuna by inhibiting NADPH-
dependent aldehyde reductase (Fukumori et al., 1979: Tabakoff and Erwin, 1970).
Satoh et al. (1979) reported that NADPH-dependent aldehyde reductase actMty is
increased by chronic treatment with barbiturates. AIthough 5-HT and 5-HIAA
concentrations in the brain do not change after chronic treatment with barbital
(Tagashira et al., 1982a), 5-HT release may increase, since 5-HT turnover
increases due to the increase in NADPH-dependent aldehyde reductase actMty.
Moreover, 5-HT and 5-HIAA concentrations in the brain increase after withdrawal
from barbiturates, and barbital withdrawal convulsions are suppressed by reduction
of the increases in 5-HT and 5-HIAA concentrations (Tagashira et al., 1982a).
Tagashira et al. (1983b) reported that co-administration of p-chlorophenylalanine
suppresses the development of physical dependence on barbital. Since p-
chlorophenylalanine decreases 5-HT metabolites and suppresses the actMty of
serotonergic neurons (Koe and Weissman, 1966), the suppressive effect of p-
chlorophenylalanine on the development of physical dependence on barbital may
result from suppression of the potentiated serotonergic neuron activity by chronic
treatment with barbital, The development of physical dependence on barbital is
potentiated and suppressed by further enhancement and inhibition of serotonergic
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neuron actMty, respectively.
   ln the present study, co-administration of imipramine, but not bifemelane or
teniloxazine, potentiated the development of physical dependence on barbital. Since
imipramine and bifemelane are both 5-HT and NE re-uptake inhibitors, monoamine
re-uptake inhibition of these drugs may not be directly involved in the development of
physical dependence on barbital. Imipramine inhibits the re-uptake of 5-HT and NE
into nerve terminals (Baldessarini, 1990), and decreases 5-HT and NE turnovers
(Egawa et al., 1983). Moreover, chronic treatment with imipramine down-regulates
5-HTiA (presynaptic autoreceptor), 5-HT2, ct2 and 6 receptors (Blier and de
Montigny, 1980; Cohen et al., 1982; Fuxe et al., 1983; Heninger and Charney, 1987;
Wolfe et al., 1978). Functional changes in these receptors suppress the actMty of
noradrenergic neurons, but potentiate the activity of serotonergic neurons and
increase the release of 5-HT from nerve terminals (BIier and de Montigny, 1980;
Cohen et al., 1982; Fuxe et al,, 1983; Heninger and Charney, 1987; Wolfe et al.,
1978). On the other hand, teniloxazine inhibits the re-uptake of NE only, and
decreases NE turnover, but increases 5-HT turnover (Anami et al., 1986). Moreover,
bifemelane inhibits the re-uptake of 5-HT and NE, and increases NE turnover, and
does not affect 5-HT turnover (Egawa et al., 1983). Chronic treatment with
bifemelane decreases NE and 5-HT turnovers, but does not regulate 6 receptor
(Egashira et al., 1989). Therefore, the differences in manipulation to serotonergic and
noradrenergic neuron actMties between imipramine and bifemelane or teniloxazine
seem to be involved in differences in the effects of these drugs on the development
of physical dependence on barbital. if the neurochemical changes induced by chronic
treatment with the combined drugs are similar to the changes induced by chronic
treatment with barbital, these drugs may potentiate the development of physical
dependence on barbital. Furthermore, if chronic treatment with the combined drugs
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produces neurochemical changes contrary to those induced by chronic treatrr}ent
with barbital, these drugs may suppress the development of physicai dependence on
barbital. Chronic treatment with both barbital and imipramine produce the
suppression of noradrenergic neuron actMties and increase 5-HT release. While,
chronic treatment with bifemelane produces the suppression of noradrenergic and
serotonerglc neuron activities. From these findings, the potentiating effect of
imipramine on the development of physical dependence on barbital may have
resulted from the further enhancement of 5-HT release and the further suppression
of the activities of noradrenergic neurons by chronic treatment with imipramine during
the barbital treatment.
   ln conclusion, these results suggest that imipramlne and bifemelane, but not
teniloxazine, potentiate barbital-induced central depression, and that co-
administration of imipramine, but not bifemelane and teniloxazine, potentiates the
development of physical dependence on barbital. The increase in magnitude of
central depression by chronic drug combination during barbital treatment, may not
relate to the development of physical dependence on barbital. If the neurochemical
changes induced by chronic treatment with the combined drugs are similar to those
induced by chronic treatment with barbital, then these drugs may potentiate the
development of physical dependence on barbital. Therefore, the development of
physical dependence on barbital may involve neurochemical changes in serotonergic
and noradrenergic neuron actMties; the further suppression of noradrenergic neuron
actMties and the further potentiation of serotonergic neuron activities that are
induced by chronic treatment with both barbital and monoamine re-uptake inhibitors
may potentiate the development of physical dependence on barbital.
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CHAPTER 2
EFFECTS OF SEROTONERGIC ANXIOLvrICS ON THE DEVELOPMENT OF
     PHYSICAL DEPENDENCE ON DIAZEPAM IN MICE AND RATS
Introduction
   Treatment with benzodiazepines is the major clinical therapy for anxiety (Katz et
al., 1991; Lader, 1991; Woods et al., 1992) and chronic treatment with
benzodiazepines is required in many clinical applications. As a result, tolerance to
and physical dependence on benzodiazepines develop, and withdrawal signs of
benzodiazepines, such as excess anxiety and convulsions, appear after termination
of benzodiazepine treatment (Hallstrom and Lader, 1981; Katz et al., 1991; Lader,
1991 ; Woods et al., 1992). Because of these problems, anxiolytic agents that lack
physical dependence liability are required. Several reports have suggested that the
central serotonergic system is involved in the induction of anxiety and in the
anxiolytic effect of benzodiazepines (Collines et al,, 1979; Costall and Naylor, 1991;
Costall et al., 1989b; Engel et al., 1984; Jones, 1990; Kahn et al., 1988; Pei et al.,
1989; Treit, 1991; Tye et al., 1979). Moreover, it has been reported that some
serotonergic agents, such as 5-HTiA agonists and 5-HT3 antagonists, are effective
anxiolytics (Colpaert et al., 1985; Costall and Naylor, l991; Costall et al,, 1989b;
1990b; Dourish et al., 1986; Engel et al., 1984; Gardner, 1986; Higgins et al., 1991;
1992; Jones et al., 1988; Kennett, 1992; Sprouse, 1991; Traber and Glaser, 1987;
Treit, 1991). Since the anxiolytic effects of serotonergic agents seem to be weaker
than those of benzodiazepines (Jann, 1988; Treit, 1991), there is a possibility that
these drugs may be used concurrently with benzodiazepines, or may replace
benzodiazepines in some cases in clinical therapy. Especially, 5-HT3 antagonists
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have been expected as a useful and dependence liability-free anxiolytics, since 5-
HTiA agonists have anxjolytic effects at low doses, but elicit anxiety at high doses
(File and Andrews, 1991; Moser et al., 1990). Although the effects of these
serotonergic agents on benzodiazepine withdrawal signs, especially withdrawal
anxiety, have been previously reported (Costall and Naylor, 1991; Costa" et al.,
1989a; 1990a; File and Andrews, 1991; Goudie and Leathley, 1990; 1991; Woods et
al., 1992), there is little information available regarding the effects of these drugs on
the development of physical dependence on benzodiazepines.
   Physical dependence on benzodiazepines has been evaluated in various animal
species and with various experimental methods (Chan et al., 1989; Goudie and
Leathley, 1990; 1991; Katz et al., 1991; Miller et al., 1990; Suzuki et al., 1992a;
Woods et al., 1992). Natural and benzodiazepine antagonist-precipitated withdrawal
signs are observed in rats chronicajly treated with benzodiazepines (Suzuki et al.,
1992a; Woods et al., 1992). However, appearance of precipitated withdrawal signs
(including convulsions) of benzodiazepines requires prolonged exposure to
benzodiazepines (for about 1 month) (Little et al., 1992; Woods et al., 1992). On the
other hand, a reliable demonstration and quantitative characterization of
benzodiazepine withdrawal signs are feasibie only by examining natural withdrawal
from benzodiazepines. The drug-admixed food method has successfully induced
severe natural withdrawal signs, including tremors and convulsions, in rats, but this
procedure also requires a prolonged and continuous exposure to benzodiazepines
(at least 1 month) (Suzuki et al. 1992a; Woods et al,, 1992). Recently, it has been
shown that chronic treatment with benzodiazepines in mice causes hypersensitMty
to the proconvulsant effect of the benzodiazepine partial inverse agonist FG 71 42
following termination of the treatment (Lister and Nutt, 1986; Little, 1988; Little et al.,
1988; Nutt and Costello, 1988). Since this procedure requires only 1 week, the
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production of convulsions by FG 7142 at proconvulsant doses after chronic treatment
with benzodiazepines in rodents has been therefore accepted as a reliable and
useful, but preliminary index for evaluating benzodiazepine-like physical dependence
liability (Lister and Nutt, 1986; Little, 1988; Little et al., 1988; Moreau et al., 1990; Nutt
and Costello, 1988; Piot et al., 1990). This procedure only evaluates FG 7142-
induced convulsion. In the present study, the effects of some serotonergic anxiolytics
on the development of physical dependence on diazepam in mice were indirectly
examined using FG 7142. In addition, the effect of ondansetron on the development
of physical dependence on diazepam in rats was directly examined by natural
withdrawal using the drug-admixed food method.
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EXPERIMENT2-1: Effects of serotonergic anxiolytics on the development of
                physical dependence on diazepam in mice.
Materials and Methods
Animals
   Male ICR mice (Charles River Japan lnc., Atsugi, Japan) that weighed 25-30 g
at the beginning of the experiment, were used. Animals were housed in groups of 5
under the conditions as described in EXPERIMENT 1-1 .
FG 7142-induced Convulsions
   Mice were treated with vehicle (10 ml/kg, i.p.)+saline (10 ml/kg, i.p.), diazepam
(16 mg/kg, i.p.)+saline, diazepam+buspirone (5-HT,A agonist; O.3, 1 and 3 mglkg,
i.p.), diazepam+mianserin (5-HTic antagonist; 5, 10 and 20 mglkg, i.p.), diazepam+
ketanserin (5-HT2 antagonist; O.1, O.3 and 1 mglkg, i.p,), diazepam+ondansetron
(5-HT3 antagonist; O.O03, O,Ol and O.03 mg/kg, i.p,), vehicle+buspirone (3 mglkg,
i.p.) or vehicle+ondansetron (O.03 mg/kg, i.p,), once a day for 7 days. Twenty-four hr
after the last treatment with drugs, mice were treated with FG 71 42 (8, 1O, 14, 20, 28,
40, 56 and 80 mg/kg, i.p,), and then,clonic-tonic convulsions induced by FG 7142
were observed for 30 min after the injection.
Plasma Concentrations of Diaze am and tts Metabolites
   Plasma concentrations of diazepam and its metabolites, nordiazepam and
oxazepam, were measured after the treatment with diazepam (16 mglkg, i.p.)+saline
(10 ml/kg, i.p.), diazepam+buspirone (3 mg/kg, i.p.) or diazepam+ondansetron (O.03
mg/kg, i.p.). After the treatment, blood was drawn from the femoral artery, and
centrifuged at 3000 rpm for 10 min to separate plasma samples. The plasma
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concentrations of diazepam and its metabolites were analyzed by high-performance
liquid chromatography according to the method of McNicholas et al. (1985) with
minor modifications. Diazepam, nordiazepam and oxazepam were used as
standards.
!D,l!ugss
   Diazepam (Profarma Co., Italy) and FG 7142 (Research Biochemicals lnc., MA,
USA) were suspended in vehicle consisting of 9 O!o Tween 80 (Kishida Chemica[ Co.,
Osaka, Japan) in saline. Buspirone hydrochloride (Sigma Chemical Co., St. Louis,
USA), mianserin hydrochloride (supplied by Zeria Pharmaceutical Co., Saitama,
Japan), ketanserin (Sigma Chemicai Co., St. Louis, USA) and ondansetron
(synthesized at Nisshin Flour Milling Co., Saitama, Japan) were dissolved in saline.
Nordiazepam and oxazepam were synthesized at Nisshin Flour Milling Co. (Saitama,
Japan).
SS!ops!lgaj-Anajys!sttstIAal
   EDso values and their 95 O/o confidence limits of FG 7142 for the clonic-tonic
convulsions were calculated by the method of Litchfield and Wilcoxon (1949),
Statistical analysis for the comparison between EDso values was carried out by
analyzing the potency ratio, This analysis was performed according to a statistical
program (Program 47 of the Pharmacologic Calculations System) aallarida and
Murray, 1987).
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Results
   Chronic treatment with diazepam did not cause any mortality or deterioratjon in
the condition of the animals. No convulsions were observed in chronically vehicle+
saline-treated mice which just received FG 7142. 0n the other hand, mice
chronically treated with diazepam showed clonic-tonic convulsions following
administration of FG 7142 in adose-dependent manner (Fig. 2-1).
   The incidence of the clonic-tonic convulsions induced by FG 7142 40 mg/kg after
the chronic treatment with diazepam in combination with serotonergic anxiolytjcs is
shown in Fig. 2-2. The incidence of the clonic-tonic convulsions was 54.05 O/o for
the diazepam+saline group. While, the incidences of the clonic-tonic convulsions for
diazepam+buspirone 3 mglkg and diazepam+ondansetron O.03 mglkg groups were
72.73 and 80.00 O/o, respectively (Fig. 2-2A, D), The incidence of the clonic-tonic
convulsions tended to be potentiated by co-administration of buspirone or
ondansetron. However, the incidence of the clonic-tonic convulsions was not
affected by co-administration of mianserin or ketanserin (Fig, 2-2B, C). Dose-
response line of FG 7142 for clonic-tonic convulsions was shifted toward Ieft by co-
administration of buspirone 3 mg/kg or ondansetron O.03 mg/kg (Fig. 2-3). EDso
values of FG 7142 for cionic-tonic convulsions were significantly decreased by co-
administration of buspirone 3 mg/kg or ondansetron O.03 mglkg ("rable 2-1, pÅqO.05).
On the other hand, no convulsions were observed in mice chronically treated with
vehicle+buspirone 3 mglkg or vehicle+ondansetron O.03 mglkg, when mice had just
received FG 7142.
   Plasma concentrations of diazepam and its metabolites, nordiazepam and
oxazepam after the treatment with diazepam were not affected by co-administration
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of buspirone 3 mglkg or ondansetron O.03 mg/kg (Fig. 2-4)
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Fig. 2-1
Dose-response Iine of FG 7142 for clonic-tonic convulsions after the chronic
treatment with diazepam. Mice were treated with diazepam (16 mg/kg, i.p.]+
saline (10 ml/kg, i.p.7, once a day for 7 days. Twenty-four hr after the tast
treatment, mice were treated with FG 7142 (10, 14, 20, 28, 40, 56 and 80
mg/kg, i.p.7, and clonic-tonic convulsions were observed for 30 min. Each
point represents the incidence of clonic-tonic convulsions calculated from 9-
37 observations. ED
                   vatue of FG 7142 for clonic-tonic convutsions was
                  5034. 16 (25.69-45.43) mg/kg.
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Fig. 2-2
Effects of chronic co-administration of serotonergic anxiolytics with
diazepam (DZP) on FG 7142-induced clonic-tonic convuisions. Mice were
treated with diazepam (16 mg/kg, i.p.)+saline (SAL; 10 ml/kg, i.p.), ÅqAÅr
diazepam+buspirone (BUS; O.3, 1 and 3 mg/kg, i.p.), ÅqBÅr diazepam+
mianserin (MIA; 5, 10 and20 mg/kg, i.p.), ÅqCÅr diazepam+ketanserin (KET;
O. 1, O.3 and 1 mg/kg, i.p.J or ÅqDÅr diazepam+ondansetron (OND; O.O03, O.Ol
and O.03 mg/kg, i.p.), once a day ior 7 days. Twenty-four hr after the Iast
treatment, mice were treated with FG 7142 (40 mg/kg, i.p.), and clonic-tonic
convulsions were observed for 30 min. Each column represents the
incidence of clonic-tonic convulsions calculated from 9-37 observations.
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Fig. 2-3
Dose-response lines of FG 7142 for cionic-tonic convulsions after the
chronic treatment with ÅqAÅr diazepam (DZP)+buspirone (BUS) or ÅqBÅr
diazepam+ondansetron (OND). Mice were treated with diazepam (16 mg/kg,
i.p.)+saline (SAL; 10ml/kg, i.p.), diazepam+buspirone (3 mg/kg, i.p.) or
diazepam+ondansetron (O.03 mg/kg, i.p.), once a day for 7 days. Tvventy-
four hr after the Iast treatment, mice were treated with several doses of
FG 7142 (10, 14, 20, 28, 40, 56 and80 mg/kg, i.p. in diazepam+saline group,
and 8, 14, 20 and 40 mg/kg, i.p. in diazepam+buspirone or diazepam+
ondansetron groups), and cionic-tonic convulsions were observed tor 30
min. Each point represents the incidence of clonic-tonic convulsions
                                value of FG 7142 for clonic-toniccalcutated from 9-37 observations. ED
                              50convulsions in diazepam+saline, diazepam+buspirone and diazepam+
ondansetron groups were 34,16 (25.69-45.43J, 20.85 (14.78-29.417 and
20.68 (14.04-30.467 mg/kg, respectivety.
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Fig. 2-4
Effects of co-administration of buspirone (BUS) or ondansetron (OND) vvith
diazepam (DZP) on plasma concentrations of diazepam and its metaboiites,
nordiazepam and oxazepam. Mice were treated with diazepam (16 mg/kg,
i.p.)+saline (SAL; 10ml/kg, i.p.), diazepam+buspirone (3 mg/kg, i.p.) or
diazepam+ondansetron (O.03 mg/kg, i.p.). Btood samples were drawn from
the femoral artery at O.5, 1, 2, 4 and 6 hr after treatment. Each point
represents the mean of 5-6 observations.
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rable 2- 1
Effects of chronic co-administration of serotonergic anxiolytics vvith
diazepam on convutsive threshold of FG7142
Treatment ED,o Of FG 7142
   (gs o/o CLJ
   mg/kg, i.p.
Potency ratio
 (95 % CL)
Diazepam 16mg/kg, i.p.
  + saline
     10 ml/kg, i.p.
  + buspirone
    3 mg/kg, i.p.
  + ondansetron
    O.03 mg/kg, i.p.
   34.16
(25. 69-45. 43)
   20.85
(14.78-29.41)
   20. 68
(14.04-30.46)
  1.64 t
(1 . 05-2. 56)
  1.6s t
(1 . 02-2. 67)
Mice were treated with diazepam (16 mg/kg, i.p.)+saiine, diazepam+
buspirone (3 mg/kg, i.p.J or diazepam+ondansetron (O.03 mg/kg, i.p.), once a
day for 7 days. Twenty-four hr after the last treatment, mice were treated
with severat doses ofFG 7142 (10, 14, 20, 28, 40, 56 and80 mg/kg, i.p. in
the diazepam+saline group, and 8, 14, 20 and 40 mg/kg, i.p. in diazepam+
buspirone or diazepam+ondansetron groups), and clonic-tonic convutsions
were observed for 30 min, EDso values and their 95 O/o confidence Iimits (CO
                                                    -were calcutated from the incidence of clonic-tonic convulsions. pÅqO.05 vs.
diazepam+saline group.
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EXPERIMENT2-2; Effect ofa serotonergic anxiolYtics, ondansetron, on the
                development ofphysical dependence on diazepam in rats
Materials and Methods
Animals
   Male Fischer 344 rats (Charles River Japan lnc., Atsugi, Japan) that weighed
130-150 g at the beginning of the experiment, were used. Animals were housed
individually under the conditions as described in EXPERIMENT 1-1.
!D,!u!gmueqypmTtmt
   As described in EXPERIMENT 1-2, diazepam alone-, diazepam+ondansetron-
and ondansetron alone-admixed food was prepared. Each rat was fed either the
diazepam alone- or diazepam+ondansetron-admixed food for 26 days, or the
ondansetron alone-admixed food for 33 days, and could drink tap water ad Iibitum,
The concentration of diazepam in the food was gradually increased during the
treatment (Table 2-2); the schedule of the diazepam treatment was according to the
method of Suzuki et al. (1992a) with minor modifications. The concentration of
ondansetron in diazepam--admixed food was fixed at O.1, O.2 or O.4 mg/g of food. On
the other hand, the concentration of ondansetron in food which contained
ondansetron alone was gradually increased during the treatment (Table 2-2). Body
weight and food consumption were measured everyday at 16:OO. Daily drug intake
was calculated according to EXPERIMENT 1-2.
pmtbtWthd l
   Abrupt withdrawal was conducted according to EXPERIMENT 1-2. Withdrawal
signs were observed after termination of the drug treatment. To quantify the intensity
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of physical dependence on diazepam, a rating score for withdrawal signs, according
to the method of Suzuki et al. (1992a) with minor modifications, was used (Table 2-
3). Withdrawal scores were calculated according to EXPERIMENT 1-2. When rats
died, their withdrawal scores in all points after death were considered to be 40.
!D,!!!,!gss
   Diazepam was purchased from Profarma Co. (ltaly)
synthesized at Nisshin Flour Mi[ling Co. (Saitama, Japan).
and ondansetron was
pmtttstcalAIsis
   Analysis of the incidence of withdrawal signs was performed using the chi-
square (2 x 2) test. Analysis for the changes in withdrawal scores was performed by
two factor (groups x times) repeated measures analysis of variance (ANOVA). All
other analyses were carried out using the Student's t-test.
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Tabte 2-2
Progressively increasing dosage schedule for chronic
treatment with diazepam or ondansetron in rats
Diazepam concentration
   (mg/g of food)
Duration
 (days)
1 and 2
2 and 4
4 and 6
  6
  8
 10
 12
3
3
4
4
3
3
6
Ondansetron concentration
    (mg/g of tood)
Dura tion
(days)
O. 05
O. 1
O.2
O.4
O.8
1.6
3.2
6.4
3
3
3
3
3
3
5
10
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Results
   There was no significant difference in daily diazepam intake during diazepam
treatment between the diazepam alone- and the diazepam+ondansetron (O.1 or O.2
mglg of food) groups, However, diazepam intake was significantly increased by co-
administration of ondansetron O.4 mg/g of food (pÅqO.Ol). The mean diazepam
intakes in the diazepam alone and diazepam+ondansetron (O.1 , O.2 or O.4 mg/g of
food) groups at the final diazepam concentration (12 mg/g of food) were 780.7 Å} 13.7,
846.2 Å} 17.7, 794,8 Å} 31 .3 and 861 .1 Å} 14.3 mg/kglday, respectively.
   After the abrupt withdrawal from diazepam, several withdrawal signs were
observed (Table 2-3). The incidence of withdrawal signs tended to be potentiated by
co-administration of ondansetron. In fact, the appearance of jerks, tremors and
convulsions were significantly potentiated (pÅqO.05). Moreover, the withdrawal scores
after abrupt withdrawal were significantly potentiated by co-administration of
ondansetron (O.1 mg/g of food: F{1 ,140]=33.409, pÅqO.Ol, O.2 mg/g of food: F[1 ,126]=
33.352, pÅqO.Ol, O.4 mg/g of food: F[1,154]=25.930, pÅqO.Ol) (Fig. 2-5). The most
potentiation of withdrawal signs was observed in the ondansetron O.2 mglg of food
co-administered group (vs. O.1 mg/g of food: F[1 ,126]=8.821 , pÅqO.Ol, vs. O,4 mg/g of
food: F{1,140]=4.060, pÅqO.05),
   In the rats that were treated with ondansetron alone, body weight gradually
increased until the ondansetron concentration reached 6.4 mglg of food, at which
weight gain was suppressed. Therefore, this concentration of ondansetron (6.4 mg/g
of food) was regarded as the final concentration of ondansetron treatment. The mean
ondansetron intake at the final ondansetron concentration was 421 .6 Å} 8.4 mg/kg/day.
After the abrupt withdrawal from ondansetron, any marked withdrawal signs were not
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observed.
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Table 2-3
Behavioral withdrawal signs for 48 hr after the abrupt withdravval from
diazepam alone or diazepam+ondansetron in rats
Positive animals / Total number of animals
Withdrawal signs
   (scores) Diazepam
  alone
      Diazepam+ondansetron
O.l mg/g O.2 mg/g O.4 mg/g
Weight ioss
 s-lo o/o a)
 10- 15 % (2J
 15%Åq (3J
Piloerection (2)
Vocalization (2)
Irritabitity (2)
Aggression (2)
Diarrhea (2)
Teeth-chattering (2)
Muscle rigidity (22
Straub tait (2)
Ear-tvvitch (2)
Lacrimation (3)
Nose-bleed (3)
Dysuria (3J
Hematuria (3)
Fascicutar-twitch (3)
Jerk (3)
Tremor (3J
Convulsion (4)
Death (4)
ev6
4/6
O/6
6/6
3/6
6/6
O/6
2/6
3/6
6/6
4/6
6/6
1/6
4/6
1/6
O/6
4/6
2/6
1/6
1/6
O/6
1/6
5/6
O/6
6/6
1/6
6/6
O/6
1/6
5/6
6/6
4/6
6/6
O/6
4/6
3/6
O/6
6/6
6/6t
4/6
216
O/6
1/5
4/5
O/5
6/6
215
5/5
O/5
O/5
4/5
5/5
5/5
5/5
3/6
3/5
3/6
2/6
5/5
4/5
4/st
4/5'
216
ev7
5/7
O/7
7/7
4/7
6/7
O/7
O/7
6/7
7/7
7/7
7!7
O/7
4/7
1/7
1/7
7/7
6/7
6/7t
4/7
1/7
'pÅqO.Os vs. diazepam-alone group.
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Fig. 2-5
Time course changes in withdrawal scores after the abrupt withdrawal from
the treatment with diazepam (DZPJ alone or diazepam+ondansetron (OND;
O. 1, O,2 or O.4 mg/g of food). Each point represents the rriean of 5-7
observations. VVithdrawai scores were significantly potentiated by co-
administration of ondansetron (O. 1 mg/g of food: Ftl, 1401=33.409, pÅqO.Ol,
O.2mg/g of food; F[1,126J=33.352, pÅqO.Ol, O.4 mg/g of iood: F(1,1541=
25.930, pÅqO.O1).
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Discussion
   Co-administration of buspirone or ondansetron with diazepam potentiated the
development of physical dependence on diazepam in evaluations using both
experimental methods: FG 7142 injection method and drug-admixed food method.
Especially, in evaluation using the drug-admixed food method, appearance rates of
severe withdrawal signs of diazepam, jerks, tremors and convulsions, after
withdrawal from diazepam were potentiated by co-administration of ondansetron.
Therefore, the potentiation of supersensitMty observed to a benzodiazepine partial
inverse agonist by co-administration of buspirone or ondansetron with diazepam
may reflect enhancement of the appearance rates of jerks, tremors and convulsions
after withdrawal.
   ln evaluation using the drug-admixed food method, diazepam intake during the
treatment was increased only by co-administration of ondansetron O.4 mg/g of food.
In general, an increase in diazepam intake during treatment potentiates the
development of physical dependence on diazepam. However, although diazepam
intake was not increased by co-administration of ondansetron O.1 and O,2 mg/g of
food, co-administration of ondansetron potentiated the development of physical
dependence on diazepam at all of the doses of ondansetron used. Moreover, the
development of physical dependence on diazepam was most potentiated in the
ondansetron O.2 mg/g of food co-administered group. These results suggest that the
potentiation by ondansetron does not result from an increase in diazepam intake.
   Co-administration of buspirone or ondansetron with diazepam potentiated the
development of physical dependence on diazepam. To determine whether or not the
enhancing effects of buspirone and ondansetron on the development of physical
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dependence on diazepam result from the pharmacokinetic interactions between
these drugs, plasma concentrations of diazepam and its metabolites were measured
after the treatment. However, plasma concentrations of diazepam and its metaboljtes
were not affected by co-administration of buspirone or ondansetron. These results
suggest that the potentiation of deveiopment of physical dependence on diazepam
by co-administration of buspirone or ondansetron is not ascribable to the
pharmacokinetic interactions between diazepam and buspirone or ondansetron.
   lt is well known that anxiety is elicited by the overstimulation of ascending
serotonergic neurons from the raphe nucleus (Biackburn, t992; Collines et al., 1979;
Costall and Naylor, 1991; Engel et al., 1984; Jones, 1990; Kahn et al., 1988; Treit,
1991; Tye et al., 1979). Benzodiazepines suppress the cell body firing rate of these
serotonergic neurons in the dorsal raphe nucleus, and reduce the release of 5-HT
from the nerve terminals of these serotonergic neurons in the amygdala,
hippocumpus and cortex (Blackburn, 1992; Costall and Naylor 1991 ; Costall et al.,
1989b; Laurent et al., 1983; Pei et al., 1989; Thiebot et al., 1980; Treit 1991). As a
result, benzodiazepines appear to produce anxiolytic effects. On the other hand,
chronic treatment with benzodiazepines results in physical dependence and causes
withdrawal signs, including excess anxiety and convulsions (Costall and Naylor 1991;
Treit 1991; Woods et al. 1992), These signs of withdrawal from benzodiazepines
have been suggested to result from increases in neurotransmitter release. In fact,
following the termination of chronic treatment with benzodiazepines, ascending
serotonergic neurons are overstimulated. As a result, the release of 5-HT from the
nerve terminals of these neurons is increased (Hitchcott et al. 1990; Wagner et al.
1985). Low doses of buspirone have been shown to bind to 5-HTiA autoreceptors
and then to decrease the cell body firing rate in the dorsal raphe nucleus and the
release of 5-HT in the amygdala (Blackburn, 1992; Dourish et al., 1986; Engel et al,,
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1984; Higgins et al., 1992; Jann, 1988; Sprouse, 1991; Traber and Glaser, 1987;
Treit, 1991), However, high doses of buspirone have been shown to bind to
postsynapse 5-HTiA receptor in the amygdala and hippocumpus, and to potentiate
these neuron actMties (File and Andrews, 1991; Moser et al., 1990). On the other
hand, ondansetron has been shown to suppress the cell body firing rate in the dorsal
raphe nucleus and to biock 5-HT3 receptors in ascending serotonergic neurons
(Costall and Naylor 1991; Costall et al., 1989a; 1989b; 1990a; 1990b; Higgins et al.,
1991; Jones et al., 1988). Ondansetron and low doses of buspirone also suppress
the signs of withdrawal from benzodiazepines, withdrawal anxiety and body weight
loss (Costall and Naylor 1991; Costall et al., 1989a; 1990a; 1990b; File and Andrews,
1991; Goudie and Leathley 1990; 1991; Woods et al., 1992). Since suppression of
general anxiety and benzodiazepine withdrawal anxiety occurs following
microinjection of ondansetron and buspirone into the dorsal raphe nucleus and
amygdala, but not into the median raphe nucleus, nucleus accumbens or caudate--
putamen (Costall and Naylor 1991; Costall et al. 1989b; 1990a; 1990b; Higgins et al.,
1991; 1992), the suppression of benzodiazepine withdrawal signs by ondansetron
and low doses of buspirone may be due to the suppression of overstimulation of
ascending serotonergic neurons, especially those from the dorsal raphe nucleus to
the amygdala (Costall and Naylor 1991; Costall et al., 1989a; 1990a; 1990b; File and
Andrews, 1991; Goudie and Leathley 1990; 1991; Woods et al., 1992). Therefore,
overstimulation of these serotonergic neurons may be involved in the appearance of
benzodiazepine withdrawal signs. The present results suggest that co-administration
of buspirone or ondansetron, but not mianserin or ketanserin, potentiates the
development of physical dependence on diazepam. Therefore, the potentiating
effects of buspirone and ondansetron on the development of physical dependence on
diazepam may eventually result from enhancement of the overstimulation of
ascending serotonergic neurons following the termination of benzodiazepine
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treatment. Moreover, it has been found that, in the rodent brain, a high density of 5-
HTiA and 5-HT3 receptors is present in the dorsal raphe necleus and amygdala, but
the densities of 5-HTic and 5-HT2 receptors in these regions are low in comparision
with those in other regions (Hoyer et al., 1992). Therefore, 5-HTiA and 5-HT3
receptors rather than 5-HTic and 5-HT2 receptors may be involved in the
overstimulation of these serotonergic neurons and in the development of diazepam
physical dependence.
   In the present evaluation using the drug-admixed food method, the development
of physical dependence on diazepam was potentiated the most by co-administration
of ondansetron O.2 mglg of food, and the potentiation by ondansetron exhibits in the
bell-shaped dose-response fashion. It is known that high dose of ondansetron does
not possess anxiolytic effect (Jones, 1990; Jone$ et al., 1988). Moreover, Goudie and
Leathley (1990) reported that high dose of ondansetron did not suppress the
benzodiazepine withdrawat signs, Since suppressing effect on diazepam withdrawal
signs and anxiolytic effect of ondansetron result from suppression of ascending
serotonergic neurons, suppression of serotonergic neuron activities by ondansetron
may exhibit in a bell-shaped dose-response curve. As a result, ondansetron
suppress the development of physical dependence on diazepam in a bell-shaped
dose-response fashion.
   Benzodiazepines bind to benzodiazepine binding sites in the GABAA '
benzodiazepine receptor / Cl- channel complex, and increase Cl- influx in the brain
(Allan et al., 1992a; Miller et al., 1988; Woods et al., 1992). Consequently,
benzodiazepines show central depresslng effects. Chronic treatment with
benzodiazepines causes the down-regulation of benzodiazepine binding sites and
subsensitivity to benzodiazepine-elicited Cl- influx in the brain (Alian et al., 1992a;
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Miller et aj., 1988; Woods et al., 1992). On the other hand, after the termination of
chronic treatment with benzodiazepines, a supersensitMty to benzodiazepine partial
inverse agonists, B-carboline analogues (FG 7142, 6-CCE, S-CCM, etc.), has been
observed in behavioral ÅqLister and Nutt, 1986; Little, 1988; Little et al., 1988; Nutt and
Costello, 1988; Woods et al., 1992) and electrophysiological (Little et al., 1992)
studies. Moreover, the decrease in the Cl' influx in the brain by FG 7142 is
potentiated following the termjnation of chronic treatment with benzodiazepines
(Allan et al., 1992a). These changes in the Cl' influx in the brain following the chronic
treatment with benzodiazepines may be directly involved in the development of
physical dependence on benzodiazepines and the appearance of benzodiazepine
withdrawal signs. In the present study, chronic treatment with buspirone or
ondansetron alone did not affect the sensitivity to the proconvulsant effect of
FG 7142. These results show that buspirone and ondansetron do not possess a
benzodiazepine-like physical dependence liability. It is known that neither buspirone
nor ondansetron has affinity to benzodjazepine binding sites (Blackburn, 1992).
Therefore, it is possible that chronic co-administration of buspirone or ondansetron
indirectly potentiates the decrease in Cl- influx after the termination of
benzodiazepine treatment, and/or directly enhances the overstimulation of
ascending serotonergic neurons following benzodiazepine withdrawal. As a result,
chronic co-administration of buspirone or ondansetron with diazepam may potentiate
the development of physical dependence on diazepam.
   Ondansetron has been shown to suppress anxiety, including that induced by
withdrawal from benzodiazepines (Costall and Naylor 4991; Costall et al., 1989a;
1989b; 1990a; 1990b; Higgins et al., 1991; Jones et al., 1988). While, buspirone also
suppresses it at only low doses, but potentiates at hjgh doses (Blackburn, 1992;
Dourish et al., 1986; Engel et al., 1984; File and Andrews, 1991; Higgins et al., 1992;
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Jann, 1988; Moser et al., 1990; Sprouse, 1991; Traber and Glaser, 1987; Treit,
1991). Therefore, the valuability of buspirone jn clinical therapy seems to be lower
than that of ondansetron. The present results and several reports (Eison, 1986; Jann,
1988, Katz et al., 1991; Lader, 1991) suggest that buspirone and ondansetron do not
possess a benzodiazepine-Iike dependence liability, but the present study revealed
that they may potentiate the development of physical dependence on
benzodiazepines. Based on these findings, since co-administration of buspirone or
ondansetron with benzodiazepines potentiates the development of physical
dependence on benzodiazepines, buspirone and ondansetron should be avoided in
benzodiazepine users, even if there is a possibility of potentiating the anxiolytic
effects of the benzodiazepines,
   ln conclusion, the present results suggest that co-administration of buspirone or
ondansetron with diazepam potentiates the development of physical dependence on
diazepam, and that regulation of serotonergic neurons through 5-HTiA and 5-HT3
receptors may be involved in the development of this physical dependence.
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CHAPTER 3
EFFECTS OF Ca2+ CHANNEL BLOCKERS ON PHYSICAL DEPENDENCE
        ON BARBrrAL AND DtAZEPAM IN RATS AND MICE
lntrod"ction
   Ca2' channel blockers are widely used as vasodilators and antiarrhythmic
agents. Specific binding sites for these drugs have been found in the periphery and
the brain (Gould et al., 1985), and recently effects of these drugs on the central
nervous system have been reported (Pucilowski, 1992; Rogawski and Porter, 1990;
Shibuya and Watanabe, 1992). Several studies suggested that Ca2' channel
blockers possess some central depressing effects such as anticonvulsant (Czuczwar
et al., t990a; 1990b; De Sarro et al., 1988; Desmedt et al., 1976; Dolin et al., 1988),
ataxic ÅqJohnston et al., 1986) and anxiolytic effects (Akaike et al., 1991).
   On the other hand, acute treatments with barbiturates (Blaustein and Ector,
1975; Elrod and Leslie, 1980; Friedman et al., 1979), ethanol (Farrar et al., 1989;
Friedman et al., 1980; Harris and Hood, 1980; Leslie et al., 1983; Stokes and Harris,
1982) and benzodiazepines (Leslie et al., 1980; 1986; Taft and DeLorenzo, 1984)
decrease Ca2' influx or Ca2' uptake, suggesting that central depressing effects of
these drugs may result from reduction of central Ca2' concentration (Friedman et al.,
1979; 1980; Leslie et al., 1980; 1986). It is known that Ca2' channel blockers
potentiate the anesthetic effects of ethanol, pentobarbital and midazolam (Dolin and
Little, 1986; Dolin et al., 1991), the anticonvulsant effect of phenobarbital (Czuczwar
et al., 1990a; 1990b), the hypothermia induced by ethanol and diazepam (Draski et
al., 1985; lsaacson et al., 1985), and the motor incoordination by ethanol, midazolam
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and clonazepam (Dolin et al., 1991; lsaacson et al., 1985). Thus, Ca2' channel
blockers seem to potentiate the central depressing effects of central depressants that
affect GABAA ' benzodiazepine receptor1Cl- channel complex.
   Chronic administration of barbiturates, ethanol and benzodiazepines develops
physical dependence and tolerance (Suzuki, 1990; Suzuki et al,, 1992a; 1992b;
Woods et al., 1992), Administration of Ca2' channel blockers, especially
dihydropyridines, during chronic ethanol treatment prevents development of
tolerance to and physical dependence on ethanol (Dolin and Little, 1989; Whittington
et al., 1991; Wu et al., 1987). Furthermore, Ca2' channel blockers suppress ethanol
withdrawal signs, when these drugs were administered systemically to ethanol-
dependent rats at the termination of ethanol treatment (LittIe et al., 1986; Littleton et
al., 1990). Therefore, it is possible that Ca2' channel blockers may be used to
suppress withdrawal signs of barbiturates or benzodiazepines, and may be used
concurrently with barbiturates or benzodiazepines to potentiate the central
depressing effects of these drugs, such as the anticonvulsant or anxiolytic effects,
and to reduce the physical dependence and toierance liability by decreasing the
required dosage of these drugs. However, the effects of Ca2' channel b[ockers on
physical dependence on barbiturates and benzodiazepines, especialiy on the
development of physical dependence on these central depressants, have been
scarcely investigated.
   ln the present study, the effects of three Ca2' channel blockers, flunarizine,
nifedipine and diltiazem on the development of physical dependence on barbital and
diazepam, and on the barbital withdrawal signs were studied. It is well known that
nifedipine and diltiazem are L-type Ca2' channel sensitive blockers, while flunarizine
is a T-type Ca2' channel sensitive blocker (Akaike et al., 1989; Louvel et al., 1986;
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Pucilowski, 1992; Rogawski and Porter, 1990; Shibuya and Watanabe, 1992;
Takahashi and Akaike, 1991; Tygat et al., 1988; Wang et al., 1990). Moreover,
flunarizine and nifedipine possess a property of high penetration into the brain
(Shibuya and Watanabe, 1992), but diltiazem possesses a property of poor
penetration (Pani et al., 1990; Shibuya and Watanabe, 1992). Therefore, the role of
two types of Ca2' channels in physical dependence on barbital and diazepam were
discussed.
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EXPERIMENT3--1:Effects of Ca2' channel blockers on the appearance of
barbital withdrawal signs in rats
Materials and Methods
Anima}s
   Male Sprague-Dawley rats (Tokyo Animal Laboratories lnc., Tokyo, Japan) that
weighed 180-230 g at the beginning of the experiment were used. Animals were
hoUsed indMdually under the conditions as described in EXPERIMENT 1-1.
Pt9)(pt91!!!!9!!!S!tm!!!!yslsl tfPh IDd
   As described jn EXPERIMENT 1-2, barbital-admixed food was prepared. Each
rat was fed the barbital-admixed food for 28 days, and could drink tap water ad
Iibitum The concentration of barbital in the food was gradually increased during the
treatment according to EXPERIMENT 1-2. Body weight and food consumption were
measured everyday at 16:OO. Daily barbital intake was calculated according to
EXPERIMENT 1-2.
Barbital Withdrawal
   Withdrawal was conducted according to EXPERIMENT 1-2. Body weight was
measured and withdrawal signs were observed after termination of the drug
treatment. Changes in body weight after withdrawal were calculated according to
EXPERIMENT 1-2. To quantify the intensity of physical dependence on barbital, a
rating score for withdrawal signs, according to EXPERIMENT 1-2 with minor
modifications, was used (Table 3-1). Withdrawal scores after the withdrawal were
calculated according to EXPERIMENT 1-2. The withdrawal scores for 42 hr (from 18
hr to 60 hr) after the withdrawal are shown as total withdrawal scores.
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Substitution of Calcium Channel Blockers
   After the withdrawal from barbital, rats were treated with saline or diltiazem (20
and 40 mglkg, i.p.) from 17 hr to 57 hr after the withdrawal at intervals of 4 hr, or
vehicle or flunarizine (20, 40 and 80 mglkg, i.p.) from 17 hr to 53 hr after the
withdrawal at intervals of 6 hr,
!D!!ygs
   Barbital was purchased from Wako Pure Chemical lnd. (Tokyo, JapanÅr.
Diltiazem hydrochloride (Sigma Chemical Co., St. Louis, USA) was dissolved in
saline, and flunarizine dihydrochloride (Sigma Chemical Co., St. Louis, USA) was
dissolved in vehicle consisting of 9 O!o Tween 80 (Kishida Chemical Co., Osaka,
Japan) in saline.
SS!g!ls!!gaj-tatst1A1ss
   Analysis for the incidence of withdrawal signs was performed using the chi-
square (2 x 2) test. Analysis for the change$ in body weight and withdrawal scores
were performed by two factor (groups x times) repeated measures analysis of
variance (ANOVA). All other analyses were carried out using the Student's t-test.
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Results
   The barbital intake was gradually increased during the treatment. The
barbital intake at the final barbital concentration (6 mg/g of food) was 389.3
mg/kg/day.
mean
+ 6.9
   After termination of the barbital treatment, several withdrawal signs were
observed (Table 3-1). The incidence of withdrawal signs during the substitution (from
18 hr to 60 hr after withdrawal) was affected by substitution of diltiazem or fiunarizine.
Flunarizine significantly suppressed the appearance of hematuria (pÅqO.05), tremor
(pÅqO.05), handling-elicited convulsions (pÅqO.05) and spontaneous convulsions
(pÅqO.Ol) as compared with vehicle treatment. On the other hand, diltiazem
significantly suppressed handling-elicited convulsions (pÅqO.05) as compared with
saline treatment, but did not affect other withdrawal signs.
   Figure 3-IA and 3-2A show the time course changes in withdrawal scores after
the termination of barbital treatment. Substitution of flunarizine or djltiazem
significantly suppressed withdrawal scores during the substitution (flunarizine 20
mg/kg: F[1,150]=34.239, pÅqO.Ol, flunarizine 40 mg/kg: F[1,150]=39.673, pÅqO.Ol,
diltiazem 20 mg/kg: F[1,150]=19.502, pÅqO.Ol). While diltiazem partially suppressed
the withdrawal scores during the substitution (Fig. 3-IA), flunarizine constantiy
suppressed the withdrawal scores (Fig. 3-2A). Figures 3-1B and 3-2B show the
areas under the curve (AUC: scores x hr) of withdrawal scores during the
substitution. The AUC of withdrawal scores during the substitution of ftunarizine (20
mg/kg: 543 Å} 32, pÅqO.05, 40 mg/kg: 511 Å} 39, pÅqO.05) were significantly lower than that
during the substitution of vehicle (775 Å} 89År (Fig. 3-2B). However, there was no
significant difference in the AUC of withdrawal scores during the substitution between
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saline group (722 Å} 22) and diltiazem 20 mglkg group (593 Å} 63) (Fig. 3-1 B). On the
other hand, total withdrawal scores during the substitution of flunarizine (20 and 40
mg/kg) were significantly lower than that during the substitution of vehicle (pÅqO.Ol)
(Table 3-1). However, there was no significant difference in the total withdrawal
scores during the substitution between saline group and diltiazem group (Table 3-1).
   Figure 3-3 shows the time course changes in body weight loss after the barbital
withdrawal. During the substitutions, weight loss was significantly reduced by
flunarizine (20 mg/kg: F[1,1501=28.179, pÅqO.Ol, 40 mg/kg: F[1,150]=20.168, pÅqO.Ol),
but not by diltiazem.
   More than half of the barbital withdrawn rats died in diltiazem 40 mglkg or
flunarizine 80 mg/kg substitution group with showing intraperitoneal hemorrhage, but
naive rats did not. As a result, these dosage of diltiazem or flunarizine may be toxic
dosage for barbital withdrawn rats.
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Table 3- I
Behavioral withdrawat signs during the substitution of dittiazem and
fiunarizine (from 18 hr to 60 hr) after the termination of barbital treatment in
rats
Positive animals / Total number of animals
VVith dra wat signs
   (scores) Saiine Dittiazem
20 mg/kg
Vehicte     Ftunarizine
20mg/kg 40mg/kg
Weight Ioss
 5- 10 % (1)
 10-15 e/. (2)
 15%Åq (3)
Piloerection (2)
Vocalization (2)
lrritability (2)
Aggression (2)
Diarrhea (2)
Teeth-chattering (2)
Muscle rigidity (2)
Straub tail (2)
Ear-twitch (2J
Lacrimation (3)
Nose-bleed (3)
Dysuria (3)
Hematuria (3)
Fascicular-tvvitch (3J
Jerk (3)
Tremor (3)
Convulsion
   Handling-elicited (3)
   Spontaneous (4J
Death (4)
3/6
2/6
O/6
6/6
6/6
6/6
3/6
O/6
5/6
6/6
6/6
6/6
1/6
216
1/6
O/6
6/6
6/6
6/6
4/6
1/6
O/6
3/6
3/6
O/6
6/6
6/6
6/6
2/6
2Y6
3/6
6/6
6/6
6/6
O/6
4/6
4/6
cr6
6/6
6/6
5/6
O/6#
2/6
O/6
1/6
3/6
1/6
6/6
5/6
6/6
1/6
1/6
4/6
6/6
6/6
6/6
O/6
5/6
5/6
4/6
6/6
6/6
6/6
5/6
5/6
O/6
4/6
1/6
O/6
6/6
6/6
6/6
O/6
O/6
3/6
6/6
6/6
6/6
O/6
4/6
276
1/6
6/6
4/6
3/6t
cr6
O/6 tt
O/6
6/6
O/6
O/6
6/6
6/6
6/6
O/6
O/6
26
6/6
6/6
6/6
O/6
ev6
cr6
O/6t
6/6
6/6
5/6
1/6 i
3/6
O/6
Total vvithdravval scores 29.5
-+ 1.5
30. 7
+ 1.5
37.2
+26
25.0 "
-+ 25
26.7"
Å} 1.6
#pÅqO.05 vs. satine substitution group.
' pÅqo.os, " pÅqO.Ol vs. vehicle substitution group.
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EXPERIMENT 3-2:Effects of Ca2+ channel blockers on the development of
physical dependence on barbital in rats
Materials and Methods
Animals
   Male Sprague-Dawley rats (Tokyo Animal Laboratories lnc., Tokyo, Japan) that
weighed 180-230 g at the beginning of the experiment were used. Animals were
housed indMdually under the conditions as described in EXPERIMENT 1-1 ,
!D2gye!gpg!gn!-gt!2!!yslgaj-PeRengggggl tfPh IDd
   As described in EXPERIMENT 1-2, barbital alone-, barbital+diltiazem- and
barbital+flunarizine-admixed foods were prepared. Each rat was fed any of drugs-
admixed foods for 28 days and could drink tap water ad Iibitum The concentration of
barbital in the food was gradually increased during the treatment according to
EXPERIMENT 1-2, The concentrations of diitiazem and fiunarizine in the food were
fixed at O.75 and 1.5 mg/g of food, respectively. Body weight and food consumption
were measured everyday at 16:OO. Daily barbital intake was calculated according to
EXPERIMENT 1 -2.
Motor lncoordination
   Motor incoordination during the drug treatments, was measured for 3 min using
rotarod performance apparatus (9 cm in diameter, 7.5 rpm; Natsume Seisakusho
Co., Tokyo, Japan). Each rat was trained to run on a rotarod until it could remain
there for 3 min without falling, before the drug treatments. The rotarod performance
test was carried out every other day.
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Barbital Withdrawal
   Withdrawal was conducted according to EXPERIMENT 1-2. Body weight was
measured and withdrawal signs were observed after the withdrawal from barbital
treatment. Changes in body weight and withdrawal scores after withdrawal were
calculated according to EXPERIMENT 3-1 .
Plasma Concentrations of Barbital after the Withdrawal
   Plasma concentrations of barbital were measured 4 times at 8 hr intervals after
the withdrawal. Rats were drawn blood samples of 400 pt1 from a tail caudal vein
using hematocrit tubes (100 pt1, Drummond Scientific Co., Pa., USAÅr, BIood samples
of 400 pl were centrifuged at 5,OOO rpm for 10 min and then plasma samples of 100
pl were separated. The plasma concentrations of barbital were analyzed by high-
performance liquid chromatography according to the method of Kabra et al. (1977)
with minor modifications.
!D!!ggs
   Barbital was purchased from Wako Pure Chemical lnd. (Tokyo, Japan), and
diltiazem hydrochloride and fiunarizine dihydrochloride were purchased from Sigma
Chemical Co. (St. Louis, USA),
SS!g!ls!i!}g!.t .atstIAl
   Analysis for the changes ln motor incoordination, body weight and withdrawal
scores was performed by two factor (groups x times) repeated measures analysis of
variance (ANOVA). All other analyses were carried out using the Student's t-test.
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Results
   There was no significant difference in daily barbital intake during barbital
treatment between the barbital alone and barbital+diltiazem or barbital+fiunarizine
groups, The mean barbital intakes in the barbital alone, barbital+diltiazem and
barbital+flunarizine groups at the final barbital concentration (6 mglg of food) were
389.3 Å} 6.9, 374.2 Å} 13,6 and 374.6 Å} 18.7 mg/kg/day, respectively, During the
treatment, motor incoordination graduaHy increased in a barbital concentration-
dependent manner (Fig. 3-4). Barbital-induced motor incoordination during the
treatment was significantly potentiated by co-administration of flunarizine (F[1 ,240]=
19.634, pÅqO,Ol), but not by co-administration of diltiazem.
   After termination of the barbital treatment, several withdrawal signs were
observed, as described in EXPERIMENT 3-1. Figure 3-5A shows the time course
changes in withdrawal scores after the termination of barbital treatment. Withdrawal
scores were significantly suppressed by co-administration of fiunarizine (F[1,168]=
20.425, pÅqO.Ol), but not by co-administration of diltiazem, Moreover, the AUCs of
withdrawal scores were 1 ,520 + 87 for barbital alone, 1 ,535 + 140 for barbital+diltiazem
and 1,126 Å} 94 for barbital+flunarizine groups (Fig. 3-5B). The AUC of withdrawal
scores in barbital+flunarizine group was significantly lower than that in barbital alone
group (pÅqO.Ol).
   As shown in Fig. 3-6, body weight decreased after termination of the barbital
treatment. The maximum weight loss was 9.49 Å} 1,20 O/o at 51 hr after the withdrawal
in the barbital alone group, 8,55 Å} 1.53 O/o at 66 hr after the withdrawal in the barbital+
diltiazem group and 7.23 Å} 2.45 O/o at 45 hr after the withdrawal in the barbital+
fiunarizine group. Weight loss after the withdrawal was significantly reduced by co-
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administration oraunarizine (F[1 ,168]=20.074, pÅqO.Ol), but not by co-administration
of diltiazem.
   Piasma concentrations of barbital after withdrawal are shown in Fig. 3-7. There
were no significant differences in plasma barbital concentrations among groups.
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EXPERIMENT3-3: Effects of Ca2' channel blockers on the development of
                physical dependence on diazepam in mice
Materiats and Methods
Animals
   Male ICR mice (Charles River Japan lnc., Atsugi, Japan) that weighed 25-30 g
at the beginning of the experiment, were used. Animals were housed in groups of 5
under the conditions as described in EXPERIMENT 1-1 .
FG 7142-induced Convulsions
   Mice were treated with vehicle (10 mVkg, i.p.)+vehicle, diazepam (16 mglkg,
i.p.)+vehicle, diazepam+nifedipine (10, 20 and 40 mg/kg, i.p.), diazepam+diltiazem
(5, 10 and 20 mglkg, i,p.) or diazepam+flunarizine (10, 20 and 40 mg/kg, i.p.), once
a day for 7 days. Twenty-four hr after the last treatment with drugs, mlce were
treated with FG 7142 (10, 14, 20, 28, 40, 56 and 80 mg/kg, i.p.), and then clonic-
tonic convulsions induced by FG 7142 were observed for 30 min after the injection.
!D,!!ggs
   Diazepam (Profarma Co,, ltaly), FG 7142 (Research Biochemicals lnc., MA,
USA) and nifedipine (Sigma Chemical Co., St. Louis, USA) were suspended, and
flunarizine dihydrochloride (Sigma Chemical Co., St. Louis, USA) was dissolved in
vehicle consisting of 9 O/o Tween 80 (Kishida Chemical Co., Osaka, Japan) in saline.
Diltiazem hydrochloride (Sigma Chemical Co., St. Louis, USA) was dissolved in
saline.
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pmtttitIA1
   EDso values and their 95 O/o confidence limits of FG 71 42 for clonic-tonic
convulsions were calculated by the method of Litchfield and Wilcoxon (1949).
Statistical analysis for the comparison between EDso values was carried out by
analyzing the potency ratio. This analysis was performed according to a statistical
program (Program 47 of the Pharmacologic Calculations System) (Tallarida and
Murray, 1987).
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Results
   Chronic treatment with diazepam did not cause any mortality or deterioration in
the condition of the animals. No convulsions were observed in chronically vehicle+
vehicle-treated mice which just received FG 7142. 0n the other hand, mice
chronically treated with diazepam showed dose-dependent clonic-tonic convulsions
following administration of FG 7142 (Fig. 2-1).
   The incidence of the clonic-tonic convulsions induced by FG 7142 40 mg/kg after
the chronic treatment with diazepam in combination with Ca2' channel blockers is
shown in Fig. 3-8. The incidence of the clonic-tonic convulsions in the group that
had been treated with diazepam+vehicle was 54.05 O/o, ln contrast, the incidences of
clonic-tonic convulsions in the diazepam+flunarizine 40 mglkg and diazepam+
nifedipine 40 mglkg groups were 41 .17 and 43.75 O/o, respectively (Fig. 3-8A, B). The
incidence of clonic-tonic convulsions tended to be suppressed by co-administration
of either flunarizine or nifedipine. On the other hand, the incidence of clonic-tonic
convulsions was not affected by co-administration of diltiazem (Fig. 3-8C). Figure 3-
9 shows dose-response lines of FG 7142 for clonic-tonic convulsions. Dose-
response line of FG 7142 was shiffted toward the right by co-administration of
flunarizine 40 mg/kg, but not by co-administration of nifedipine 40 mglkg. ED,o
values of FG 71 42 for clonic-tonic convulsions in the diazepam+flunarizine 40 mg/kg
and diazepam+nifedipine 40 mg/kg groups were 59.37 (39.82-88.51) and 45.28
(22.47-91.25) mglkg, respectively. The potency ratio of the ED,o values of FG 7142
for the diazepam+vehicle and diazepam+flunarizine 40 mglkg groups was 1.74
(1.06-2.84), which indicates that FG 7142-induced clonic-tonic convulsion was
significantly suppressed by the co-administration of flunarizine (Table 3-2, pÅqO.05).
However, the potency ratio of the EDso values of FG 7142 for the diazepam+vehicle
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and diazepam+nifedipine 40 mg/kg groups was 1.33 (O.62-2.82), suggesting that the
co-administration of nifedipine did not affect FG 7142-induced clonic-tonic
convulsion aable 3-2).
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Table 3-2
Effects of chronic co-administration of Ca2' channel blockers with diazepam
on convulsive threshotd of FG 7142
Treatment EDso Of FG 7142
   (gs o/. cL)
   mg/kg, i.p.
Potency ratio
 (95 O/. CL)
Diazepam 16mg/kg, i.p.
  + vehicle
      10 ml/kg, i.p.
  + fiunarizine
      40 mg/kg, i.p.
  + niiedipine
      40 mg/kg, i.p.
   34.16
(25. 69-45. 43)
   59.37
(39. 82-88. 51)
   45.28
(22.47-91.25)
   1. 74 t
(1 . 06-2. 84)
   1.33
(O. 62-2. 82)
Mice were treated with either diazepam (16 mg/kg, i.p.)+vehicle (10 ml/kg,
i.p.), diazepam+fiunarizine (40 mg/kg, i.p.) or diazepam+nifedipine (40
mg/kg, i.p.], once a day for 7 days. Twenty-four hr after the Iast treatment,
mice were treated with several doses of FG 7142 (10, 14, 20, 28, 40, 56 and
80 mg/kg, i.p. in the diazepam+vehicte group, and 14, 20, 40, 56 and 80
mg/kg, i.p. in diazepam+flunarizine or diazepam+niiedipine groups), and
clonic-tonic convulsions were observed for 30 min. EDso values and their 95
O/o confidence Iimits (CL) vvere calculated from the inctdence of clonic-tonic
convutsions. 'pÅqO.05 vs. the diazepam+vehicle group.
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Fig. 3-8
Effects of chronic co-administration of Ca2' channel biockers with diazepam
(DZP) on FG 7142-induced clonic-tonic convulsions. Mice were treated with
diazepam (16 mg/kg, i.p.)+vehicte (fO mt/kg, i.p.), ÅqAÅr diazepam+fiunarizine
(FLU; 10, 20 and 40 mg/kg, i.p.), ÅqBÅr diazepam+nifedipine (N/F; 10, 20 and
40 mg/kg, i.p.J or ÅqCÅr diazepam+diltiazem (DIL; 5, 10 and 20 mg/kg, i.p.),
once a day for 7 days. Twenty-four hr after the tast treatment, mice were
treated with FG 7142 (40 mg/kg, i.p.J, and cionic-tonic convuisions vvere
obsetved for 30 min. Each column represents the incidence oi ctonic-tonic
convulsions calculated from 9-37 observations.
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Dose-response lines of FG 7142 for clonic-tonic convulsions after the
chronic treatment vvith ÅqAÅr diazepam (DZP)+tlunarizine (FLU) or ÅqBÅr
diazepam+niiedipine (NIF). Mice were treated with diazepam (16 mg/kg,
i.p.J+vehicte (10mt/kg, i.p.J, diazepam+flunarizine (40mg/kg, i.p.) or
diazepam+niiedipine (40 mg/kg, i.p.J, once a day for 7 days. Twenty-four hr
after the Iast treatment, mice were treated with several doses of FG 7142
(10, 14, 20, 28, 40, 56 and 80 mg/kg, i.p. in diazepam+vehicle group, and 14,
20, 40, 56 and 80 mg/kg, i.p. in diazepam+fiunarizine or diazepam+nifedipine
groups), and ctonic-tonic convutsions were observed for 30 min. Each point
represents the incidence of clonic-tonic convutsions calcutated from 9-37
                 value of FG 7142 for ctonic-tonic convulsions inobservations. ED
               50diazepam+vehicte, diazepam+fiunarizine and diazepam+nifedipine groups
were 34.16 (25.69-45.43), 59.37 (39.82-88.51) and 45.28 (2247-91.25)
mg/kg, respectively.
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Discussion
   Co-administration of flunarizine with barbital significantly potentiated barbital-
induced motor incoordination, and suppressed development of physjcal dependence
on and appearance of withdrawal signs of barbital, While, diltiazem did not affect the
barbital-induced motor incoordination and the development of physicai dependence
on barbjtal. Moreover, the suppression of barbital withdrawal signs by diltiazem was
partial and very weak. In addition, co-administration ef flunarizine, but not of either
nifedipine or diltiazem, suppressed the development of physical dependence on
diazepam. It is well known that diltiazem penetrates poorly into the brain, as
compared to either flunarizine or nifedipine (Pani et al., 1990; Shibuya and
Watanabe, 1992). Therefore, L-type Ca2' channels in the periphery may not be
involved in the development of physical dependence on and appearance of
withdrawal signs of these central depressants.
   Benzodiazepines (Leslie et ai., 1980; 1986; Taft and DeLorenzo, 1984),
barbiturates (Blaustein and Ector, 1975; Elrod and Leslie, 1980; Friedman et al.,
1979) and ethanol ÅqFarrar et al., 1989; Friedman et al,, 1980; Harris and Hood, 1980;
Leslie et al., 1983; Stokes and Harris, 1982) decrease Ca2' influx or uptake into brain
synaptosomes, which suggests that the central depressing effects of these drugs
may be related to the reduction of Ca2' concentrations in brain synaptosomes (Elrod
and Leslie, 1980; Friedman et al., 1979; 1980; Lesiie et al,, 1980; 1986). Ca2'
channel blockers are known to potentiate the central depressing effects of these
drugs (Czuczwar et al., 1990a; 1990b; Dolin and Little, 1986; Dolin et al., 1991;
Draski et al., 1985; lsaacson et al., 1985). In fact, in the present study, co-
administration of flunarizine potentiated the central depressing effect (motor
incoordinationÅr of barbital. It is believed that these potentiation by Ca2' channel
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blockers may resujt from further reduction of Ca2' concentrations in brain
synaptosomes (Czuczwar et al., 1990a; 1990b; Dolin and Little, 1986; Dolin et al.,
1991; Draski et al,, 1985; lsaacson et al., 1985).
   ln general, it is known that the severity of physical dependence on sedative
hypnotics such as barbiturates, ethanol and benzodiazepines, relates to the
magnitude of central depression during treatment (Suzuki, 1990; Tagashira et al.,
1978; 1979). For example, Tagashira et al. (1981) reported that increase in
magnitude of central depression by combination of a dependence liability-free drugs
(such as chlorpromazine) during the phenobarbital treatment, induced the
potentiation of the development of physical dependence on phenobarbital. On the
contrary, in the present study, although co-administration of fiunarizine potentiated
the barbital-induced motor incoordination, it suppressed the development of
physical dependence on barbital and diazepam. The potentiating effect of
chlorpromazine on central depression by and the development of physical
dependence on phenobarbital, may result from the inhibition of monoamine re-
uptakes and changes in actMties of monoamine-related neurons by chlorpromazine
(Tagashira et al., 1981). Furthermore, it has been suggested that the potentiating
effects of Ca2' channel blockers on the central depression of these sedative
hypnotics may be ascribable to further reduction of central Ca2' concentration
(Czuczwar et al., 1990a; 1990b; Dolin and Little, 1986; Dolin et al., 1991; Draski et
al., 1985; lsaacson et al., 1985). On the other hand, it is known that tolerance to and
physical dependence on sedative hypnotics may well relate to changes in regulation
of central Ca2' channels (Dolin and Little, 1989; Elrod and Leslie, 1980; Farrar et al.,
1989; Friedman et al., 1980; Harris and Hood, 1980; Leslie et al., 1980; 1983; Little et
al., 1986; Littleton et al., 1990; Wu et al., 1987). Therefore, the suppressing effect of
flunarizine on the development of physical dependence on barbital and diazepam
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may result from changes in regulation of central Ca2' channel rather than from
changes in central Ca2' concentration.
   Boisse and Okamoto (1978) reported that barbiturate withdrawal signs may be
inversely related to residual blood barbiturate concentrations. There is a possibility
that co-administration of flunarizine affects the disappearance rate of barbital.
Therefore, plasma concentrations of barbital after the withdrawal were mesured.
However, there were no differences in plasma concentrations of barbital after the
withdrawal between barbital aione and barbital+flunarizine groups. These results
suggest that the suppression of development of physical dependence on barbital by
flunarizine is not ascribable to a pharmacokinetic interaction.
   Chronic treatment with central depressants such as ethanol, barbiturates and
benzodiazepines, develops tolerance and physical dependence, and causes an up-
regulation of central Ca2' channel and/or an increase in central Ca2' influx in brain
synaptosomes (Dolin and Little, 1989; Elrod and Leslie, 1980; Farrar et al., 1989;
Friedman et al., 1980; Harris and Hood, 1980; Leslie et al., 1980; 1983; Little et al.,
1986; Littleton et al., 1990; Wu et al., 1987). Withdrawal signs of these drugs have
been believed to result from increases in transmitter release that are evoked by
supersensitMty of the nerve terminals to Ca2' (Chugh et al., 1992; Dolin et al., 1990;
Little et al., 1986; Littleton et al., 1990). Ca2' channel blockers may suppress this
evoked increase in transmitter release, and thus suppress the signs of withdrawal
from these drugs (Chugh et al,, 1992; Dolin et al,, 1990; Little et al., 1986; Littleton et
al., 1990). Moreover, nitrendipine prevents the development of tolerance to and
physical dependence on ethanol by preventing the up-regulation of dihydropyridine
binding sites in the brain (Dolin and Little, 1989; Whittington et al., 1991), ln addition,
chronic treatment with some Ca2' channel blockers, e.g. nifedipine, verapamil, etc.
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induces a down-regulation of central Ca2' channel (Panza et al., 1985). Based on
these findings, it is believed that up-regulation of Ca2' channels in the brain
induced by chronic treatment with these central depressants may be involved in the
development of tolerance to, physical dependence on, and the appearance of signs
of withdrawal from these drugs. In particular, L-type Ca2' channels in the brain may
be involved in the tolerance to and physical dependence on ethanol (Dolin and Little,
1989; Whittington et al., 1991). In the present study, co-administration of flunarizine
significantly suppressed the development of physical dependence on diazepam and
barbital, but co-administration of nifedipine did not affect the development of physical
dependence on diazepam. Suzuki et al. (1990) reported that co-administration of
nifedipine did not suppress the development of physical dependence on barbital.
Moreover, Dolin et al. (1990) reported that co-administration of nitrendipine does not
suppress the development of tolerance to and physical dependence on
benzodiazepines. These findings and the present results suggest that the
developments of tolerance to and physical dependence on benzodiazepines and
barbiturates are suppressed by co--administration of a T-type Ca2' channel sensitive
blocker, but not of L-type Ca2+ channel sensitive blockers, and that the up-regulation
of T-type Ca2' channels in the brain, but not of L-type Ca2' channels, may be
involved in tolerance to and physical dependence on benzodiazepines and
barbiturates.
   Benzodiazepines and barbiturates bind to each binding site in the GABAA '
benzodiazepine receptor / Cl- channel complex, and increase Cl- influx in the brain
(Allan et al., 1992a; 1992b; Woods et al., 1992). Consequently, benzodiazepines and
barbiturates show central depressing effects. Chronic treatment with
benzodiazepines and barbiturates develops tolerance and causes the subsensitivity
to benzodiazepine and barbiturates-elicited Cl- influx in the brain (Allan et al., 1992a;
93
1992b; Miiler et al., 1988; Woods et al., 1992). On the other hand, after the
termination of chronic treatment with benzodiazepines or barbiturates, a
supersensitivity to benzodiazepine partial inverse agonists, i.e., P-carboline
analogues (FG 7142, 6-CCE, 6-CCM, etc.), and Cl- channel negative modulators,
e.g. pentylenetetrazol, picrotoxin, has been observed (Lister and Nutt, 1986; Ljttle,
1988; Little et al,, 1988; 1992; Nutt and Costello, 1988; Tagashira et al., 1982b;
Woods et al., 1992). Moreover, the decrease in the Cl- influx in the brain by FG 71 42
is potentiated following the termination of chronic treatment with benzodiazepines
(Allan et al., 1992). These changes in the Cl- influx in the brain following the chronic
treatment with benzodiazepines or barbiturates may be directly involved in the
development of physical dependence on and the appearance of withdrawal signs of
benzodiazepines and barbiturates. In the present study, co-administration of
flunarizine, but not of nifedipine, suppressed the development of physical
dependence on diazepam and barbital. Therefore, changes in the sensitMty of T-
type Ca2' channels in the brain, rather than L-type Ca2' channels, may be related to
the changes in the Cl- influx in the brain following chronic treatment with
benzodiazepines or barbiturates.
   ln the present study, flunarizine markedly suppressed the barbital withdrawal
signs, especially convulsions. Flunarizine selectively blocks T-type Ca2' channel
(Akaike et al., 1989; Louvel et al,, 1986; Pucilow$ki, 1992; Rogawski and Porter,
1990; Shibuya and Watanabe, 1992; Takahashi and Akaike, 1991; Tygat et al., 1988;
Wang et al., 1990), Phenytoin, an antiepileptic drug and a $elective T-type Ca2'
channel and Na' channel blocker (Coulter et al., 1989; Rogawski and Porter, 1990;
Takahashi et al., 1989; Yaari et al., 1987), suppresses withdrawal convulsions
induced by barbital (Tagashira et al., 1981). Moreover, Little et al. (1986) and
Littleton et al. (1990) reported that flunarizine prevents ethanol withdrawal
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convulsions, and Chugh et al. (1992) also reported that cinnarizine, a selective T-
type Ca2' channel blocker, prevents diazepam withdrawal signs. Since withdrawal
signs of ethanol and diazepam are caused by increases in evoked transmitter
release owing to supersensitMty of the nerve terminals to Ca2", Ca2' channel
blockers may prevent the supersensitMty to Ca2'. As a result, Ca2' channel blockers
may prevent withdrawal signs of these sedative hypnotics (Chugh et al., 1992; Dolin
et al., 1990; Little et al., 1986; Littleton et al., 1990). Therefore, the suppression of
barbital withdrawal signs by flunarizine may result from blockade of T-type Ca2'
channel.
   Flunarizine has been shown to possess anticonvulsant properties in laboratory
animals and humans (Astarloa et al., 1989; De Sarro et al., 1988; Desmedt et al.,
1976), and this anticonvulsant effect of flunarizine may result from T-type Ca2'
channel blockade (Pucilowski, 1992; Rogawski and Porter, 1990; Shibuya and
Watanabe, 1992). In the present study, chronic co-administration of flunarizine
suppressed the development of physical dependence on barbital and diazepam.
These findings suggest that the adequate co-administration of T-type Ca2' channel
sensitive blockers and either benzodiazepines or barbiturates may be a useful
method for producing a potent antiepileptic action accompanied by decreasing the
potential for physical dependence on the benzodiazepines or barbiturates.
   ln conclusion, the present results suggest that chronic co-administration of
flunarizine, but not of either nifedipine or diltiazem, with barbital or diazepam
suppresses the development of physical dependence on barbital or diazepam, and
substitution of flunarizine, but not diltiazem, suppresses the appearance of barbital
withdrawal signs. This effects of flunarizine may be mainly due to suppression of
withdrawal convulsions of barbital and diazepam by reducing the Ca2' influx and
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preventing up-regulation of Ca2' channel. The differences between fiunarizine and
either nifedipine or diltiazem may result from differences in the types of Ca2' channel
in the brain; unlike ethanol, T-type Ca2' channels in the brain rather than L-type
Ca2' channels may be involved in the physical dependence on barbital and
diazepam,
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Tabte 3-3
Modification of pysical dependence on
Ca2+ channet blockers
central depressants by two types of
L-type Ca2' channel
 sensitive blockers
T-type Ca2' channel
 sensitive btockers
Ethanol
   Physical dependence
Withdrawalsigns
Barbiturates
   Physical dependence
Withdrawalsigns
    suppresslon
(VVhittington et aL, 1991)
    suppresston
  (LittIe et aL, 1986)
  suppresston
(LittIe et aL, 1986)
    no effect
(Suzuki et aL, 1990)
  suppresslon
(Brovvn et aL, 1988)
 suppresslon
(present resutts)
 suppresston
(present results]
   Physical dependence
   Withdrawal signs
   no effect
(Dolin et aL, 1990)
  suppression
(Dotin et aL, 1990)
  suppression
 (present resutts)
  suppression
(Chugh et aL, 1992)
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GENERAL DISCUSSION
   Barbiturates and benzodlazepines both categorized in sedative hypnotics are
widely known to commonly work on GABAA ' benzodiazepine receptor 1 Cl" channel
complex, to increase CI" influx (Akaike, 1989; Harrison et al., 1988) and decrease
Ca2' influx (Friedman et al., 1979; Leslie et al., 1980); as a result, these drugs
suppress several central neuron actMties (Akaike, 1989; Harrison et al., 1988). It is
considered that central depressing effects of these drugs such as anxiolytic,
anticonvulsant, sedative and hypnotic effects and ataxia, may be induced by the
suppression of neuron actMties (Rogawski and Porter, 1990). As a vital question,
chronic treatment with any these drugs produce physjcal dependence. Physical
dependences on barbiturates and benzodiazepines are able to substitute each other
(Yanagita and Takahashi, 1973). This phenomenon is called cross physical
dependence. Therefore, barbiturates and benzodiazepines are categorized in the
same class of substance dependence "barbiturates type" in the WHO classification
(Kramer and Cameron, 1975). In this context, barbital and diazepam were chosen in
the present study as representatives of barbiturates and benzodiazepines
respectively to study "barbiturates type" dependence.
   The mechanisms of physical dependence on these drugs have not yet been
clear. These drugs have been suggested to show the central depressing effects by
suppressing the Ca2' influx and several neuron actMties including noradrenergic and
serotonergic neuron actMties (Akaike, 1989; Friedman et al., 1979; Harrison et al.,
1988; Leslie et al., 1980; Rogawski and Porter, 1990). The development of physical
dependece on these drugs may therefore relate to changes in the responsiveness of
Ca2' channel and the neuron activities. In the present study, the involvements of 1)
changes in the activities of noradrenergic and serotonergic neurons, 2) four types of
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5-HT receptors and 3) two types of Ca2' channels, in the development of physical
dependence on barbiturates and benzodiazepines were thus examined. Barbiturates
and benzodiazepines suppress the activities of noradrenergic and serotonergic
neurons by jncreasjng Cl- inf)ux and decreasjng Ca2' jnflux. tt js known that chronjc
treatments with barbiturates and benzodiazepines produce the down-regulation of
GABAA ' benzodiazepine receptor / CI' channel complex (Alian et al., 1992a; 1992b;
Miller et al., 1988; Woods et al,, 1992) and the up-regulation of Ca2" channels (Elrod
and Leslie, 1980; Leslie et al., 1980). As a result, the suppressing effects of
barbiturates and benzodiazepines on the noradrenergic and serotenergic neuron
activities become gradually tolerant during chronic treatment with these drugs
(Tagashira et al., 1982a; 1983a; Woods et al., 1992). Therefore, the noradrenergic
and serotonergic neurons are overstimulated as a rebound phenomenon after the
termination of barbiturates or benzodiazepines (Costall and Naylor, 1991; Tagashira
et al., 1982a; 1983a; Woods et al., 1992), and withdrawal signs pf these drugs are
considered to result from the overstimulation of noradrenergic and serotonergic
neurons. In the present study, chronic co-admjnistratjon of imjpramjne, tricycljc
antidepressant, with barbital potentiated the development of physical dependence on
barbital. This raises the possibility that chronic co-administration of imipramine with
barbital produces the potentiation of the overstimulation of noradrenergic and
serotonergic neurons after the termination of barbital. Whije, acute treatment wjth
imipramine suppresses the activities of noradrenergic and serotonergic neurons
(Egawa et al., 1983), the suppressing effect of imipramine on the noradrenergic and
serotonergic neuron actMties becomes gradually tolerant during chronic treatment
with imipramine by down-regulation of a2 autoreceptor in iocus coeruleus (Svensson
and Usdin, 1978) and by an increase in 5-HT release in cortex and hippocampus
(Heninger and Charney, 1987). As a consequence, serotonergic neuron actMties
become above the pre-drug level, but noradrenergic neuron actMtes are still slightly
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below the pre-drug level after chronic treatment with imipramine (Heninger and
Charney, 1987; Svensson and Usdin, 1978). As above described, barbitai
suppresses these neuron activities by increasing Cl' influx and decreasing Ca2'
influx, but this suppression becomes gradualiy tolerant during chronic treatment with
barbital by down-regulating GABAA ' benzodiazepine receptor l Cl- channel complex
and up-regulating Ca2' channels (Satoh et ai., 1979; Tagashira et al., 1982a;
1983a). Serotonergic neuron activities are also increased by enhancement of
NADPH-dependent aldehyde reductase actMties which is induced by chronic
treatment with barbital (Satoh et al., 1979). As a result, serotonergic neuron activities
are totally potentiated, but noradrenergic neuron activites are still slightly suppressed
after chronic treatment with barbital. After all, chronic treatment with barbital or
imipramine apparently suppresses noradrenergic neuron actMties and potentiates
serotonergic neuron activities, Therefore, chronic co-administration of imipramine
with barbital may potentiate the development of physical dependence on barbital by
chronically superimposition of the alteration of noradrenergic and serotonergic
neuron activities induced by chronic treatment with barbital. In addition, 5-HTiA
agonist, buspirone, and 5-HT3 antagonist, ondansetron, but not 5-HTic antagonist,
mianserin, and 5-HT2 antagonist, ketanserin, potentiated the developrnent of
physical dependence on diazepam in the present study. It is known that anxiolytic
effects of buspirone and ondansetron result from suppression of actMties of
ascending serotonergic neuron (from dorsal raphe neucleus to amygdala) through 5-
HTiA receptors (autoreceptors) and 5-HT3 receptors, respectively (Blackburn, 1992;
Costall and Naylor, 1991 ; Treit, 1991). After the termination of chronic treatment with
tricyclic antidepressants, rebound symptoms (hyper-responsiveness of
noradrenergic and serotonergic neurons) are induced by gradual tolerance to the
suppression of noradrenergic and serotonergic neuron activities during chronic
treatment with tricyclic antidepressants (Nutt and Giue, 1991), Whereas, unlike
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tricyclic antidepressants, after the termination of chronic treatment with buspirone or
ondansetron, general behavior did not change. Therefore, the suppression of
ascending serotonergic neuron activities by buspirone or ondansetron may not
become tolerant during chronic treatment with buspirone or ondansetron. While acute
diazepam also suppresses the ascending serotonergic neuron actMties by
increasing Cl- influx and decreasing Ca2' influx (Costall and Naylor, 1991; Treit,
1991), this suppression become gradually tolerant during chronic treatment with
diazepam by down-regulating GABAA ' benzodjazepjne receptor / Cl- channel
complex and up-regulating Ca2' channels in dorsal raphe nucleus (Hitchcott et al,,
1990; Wagner et al., 1985). Therefore, chronic co-administration of buspirone or
ondansetron with diazepam may have potentiated the development of physical
dependence on diazepam, owing to the potentiation of these functional changes in
GABAA ' benzodiazepine receptor / Cl- channel complex and Ca2' channels by
further suppressing the ascending serotonergic neuron actMties through 5-HTiA and
5-HT3 receptors. On the other hand, in the present study, chronic co-administration
of T-type Ca2' channel sensitive biocker, flunarizine, with barbital or diazepam
suppressed the development of physical dependence on barbital or diazepam, but L-
type Ca2' channel sensitive blockers, nifedipine and diltiazem did not. Chronic
treatment with Ca2' channel blockers reportedly produces the down-regulation of
Ca2' channels (Panza et al., 1985), Therefore, flunarizine may have suppressed the
development of physical dependence on barbiturates and benzodiazepines by
suppressing the up-regulation of T-type Ca2' channel that was inevitably induced
by chronic treatment with barbiturates and benzodiazepines, ln these perspectives, it
would be claimed that the development of "barbiturates type" physical dependence
may be modified by modulating the alterations of GABAA ' benzodiazepine receptor /
Cl- channel complex, Ca2' channel and noradrenergic and serotonergic neuron
actMties which are induced by chronic treatments with barbiturates and
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benzodiazepjnes.
   Barbiturates and benzodiazepines are widely used as anxiolytics, antiepileptics,
hypnotics, muscle-relaxants or antidepressants, in clinical therapy. However, as a
matter of significance, chronic treatments with barbiturates and benzodiazepines
produce physical dependence. Therefore, there is a diverse probability that
barbiturates or benzodiazepines may be used concurrently with other drugs to
potentiate their central depressing action and to decrease their potential for physical
dependence liability. In fact, barbiturates or benzodiazepines have been treated in
combination with other antiepileptics (Delgodo-Escueta and Enrile-Bacsal, 1983)
and tricyclic antidepressants (Nutt and Glue, 1991) in clinjcal use. In the present
study, 'a tricyclic antidepressant, imipramine, potentiated the development of physical
dependence on barbital, Therefore, it is recommended that tricyclic antidepressants
should be avoided to be used concurrently with barbiturates or benzodiazepines.
Furtherrnore, in the present study, 5-HTiA agonist, buspirone, and 5-HT3 antagonist,
ondansetron, potentiated the development of physical dependence on diazepam.
Buspirone and ondansetron have recently been expected as safe and useful
anxiolytics which possess no physical dependence liability (Costall and Naylor, 1991 ;
Treit, 1991). Buspirone and ondansetron may well be expected to be used together
with benzodiazepines clinically, since anxiolytic effects of these drugs are weaker
than those of benzodiazepines (Jann, 1988; Treit, 1991). However, it is suggested
with a warning from the present results that these combinations potentially have a
risk of augmentation of physical dependence in clinical use. On the other hand, in the
present study, T-type Ca2' channel sensitive blocker, flunarizine, suppressed the
developments of physical dependence on barbital and diazepam and the appearance
of barbital withdrawal signs. It is also reported that T-type Ca2' channel sensitive
blockers suppress the appearance of withdrawal signs of benzodiazepines (Chugh et
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al., 1992). The T-type Ca2' channel sensitive blockers, ethosuximide, fiunarizine and
cinnarizine share anticonvulsive actions (Desmedt et al., 1976; Rogawski and Porter,
1990). Especially, ethosuximide has been used for therapy of absence status
epilepticus (Rogawski and Porter, 1990). Flunarizine has been used to cerebral
circulation trouble in clinical therapy, However, flunarizine was recently reported to
potentiate anticonvulsive action of antiepileptjcs in animals and humans (Overweg et
al., 1984; Rogawski and Porter, 1990), Therefore, the combination of T•-type Ca2'
channel sensitive blockers and barbiturates or benzodiazepines may be a useful
strategy for producing a potent antiepileptic action and, from the present finding, for
decreasing the potential for physical dependence liability on barbiturates or
benzodiazepines.
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CONCLUSION
   Barbiturates and benzodiazepines commonly affect GABAA ' benzodiazepine
receptor / Cl- channel complex and produce the same class of substance
dependence "barbiturates type". In the present study, the involvements of changes in
the activities of noradrenergic and serotonergic neurons and adaptation of some 5-
HT receptors and Ca2' channels, in the development of physical dependence on
barbiturates and benzodiazepines were investigated. The conclusion of the present
study are shown as follows:
1. The development of physical dependence on barbital was potentiated by chronic
co-administration of imipramine, but not bifemelane or teniloxazine. The
development of barbiturates physical dependence may be potentiated by further
suppression of noradrenergic neuron actMties and further potentiation of
serotonergic neuron actMties during the development of physical dependence.
2. The development of physical dependence on diazepam was potentiated by
   chronic co-administration of buspirone or ondansetron, but not mianserin or
   ketanserin, The development of benzodiazepine physical dependence may be
   potentiated by superimposition of suppression of the ascending serotonergic
   neuron actMties, that are suppressed by chronic treatment with diazepam aione,
   through 5-HTiA and 5-HT3 receptors.
3. The development of physical dependence on barbiturates and benzodiazepines
   was suppressed by chronic co-administration of flunarizine, but not nifedipine or
   diltiazem, The development of physical dependence on barbiturates and
   benzodiazepines may be suppressed by prevention of the up-regulation of T-
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type Ca2' channel which was induced by the development of physical
dependence on barbiturates and benzodiazepines. Moreover, the appearance of
withdrawal signs of central depressants is suppressed by T-type Ca2' channel
blockade.
4. The intensity of physical dependence on barbiturates and benzodiazepines may
   be related to the several neuromodulation rather than to the changes in the
   magnitude of central depression by chronic drug combination during the
   development of physical dependence.
5. Since tricyclic antidepressants, 5-HTiA agonists or 5-HT3 antagonists potentiate
   the development of physical dependence on barbiturates and benzodiazepines,
   these combinations should be avoided. On the other hand, co-administration of
   T-type Ca2' channel sensitive blockers and barbiturates or benzodiazepines
   may be a useful method for producing a potent antiepileptic action and
   decreasing the potential for physical dependence on barbiturates and
   benzodiazepines.
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